

06-08-00

A

SEQ BOX

"EXPRESS MAIL CERTIFICATE"**"EXPRESS MAIL" MAILING LABEL NUMBER EL437304757US****DATE OF DEPOSIT JUNE 7, 2000**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST
OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, DC 20231.

NAME OF PERSON MAILING PAPER OR FEE**(TYPE OR PRINT) TRACY WESTPHAL****SIGNATURE***Tracy Westphal*

Docket No. 1121

June 7, 2000

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL

Inventor(s): Pramod B. Mahajan

Title: Maize Orthologues of Bacterial RuvB: cDNAs and Uses Thereof

APPLICATION ELEMENTS1. ☐ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)2. ☒ Specification [Total Pages 69]

(Preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☐ Drawing(s) (35 USC 113) [Total Sheets]

- a. ☐ Formal
- b. ☐ Informal

06/07/00



JCS6 U.S. PTO



JCS6 U.S. PTO

09/589510

06/07/00

09589510-060700

4. ☒ Oath or Declaration [Total Pages 2]
a. ☒ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4B is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. ☒ Computer Readable Copy
b. ☒ Paper Copy (identical to computer copy) [Total Pages 17]
c. ☒ Statement verifying identity to above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(where there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS/PTO-1449) ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
14. ☐ Small Entity Statement(s) ☐ Statement filed in prior application
Status still proper and desired

15. ☐ Certified Copy of Priority document(s)

16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check the appropriate box and supply the requisite information: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____.

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label: _____
(Insert Customer No. or Attach bar code label here)

or

☒ Correspondence address below

Name: Amy L. Cigan

Address: Pioneer Hi-Bred International, Inc.
Corporate Intellectual Property
7100 N.W. 62nd Avenue
P.O. Box 1000

City Johnston State: Iowa Zip Code: 50131-1000

Country: USA Phone: (515) 248-4896 Facsimile: (515) 334-6883

19. FEE CALCULATION

☒ The total fee is calculated as shown below:

Basic Filing Fee					\$ 690.00
Total Claims	13 - 20	= 0	x	\$ 18.00	0.00
Independent Claims	9 - 3	= 6	x	\$ 78.00	468.00


☐ Multiple Dependent Claims present + \$260.00 \$

TOTAL FILING FEE \$1158.00

Attorney Docket No.: 1121

- ☒ Charge \$1158.00 to Deposit Account No. 16-1852.
- ☒ The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. 16-1852.
- ☒ A duplicate of this transmittal is enclosed

Respectfully submitted,


Amy L. Cigan
Agent for Applicant(s)
Registration No. 45,494

PIONEER HI-BRED INTERNATIONAL, INC.
Corporate Intellectual Property
7100 N.W. 62nd Avenue
P.O. Box 1000
Johnston, Iowa 50131-1000
Phone: (515) 248-4896
Facsimile: (515) 334-6883

PATENT APPLICATION

Maize Orthologues of Bacterial RuvB: cDNAs and Uses Thereof

Inventors: Pramod B. Mahajan
8029 Brookview Drive
Urbandale, IA 50322
Citizen of the United States of America

Assignee:
PIONEER HI-BRED INTERNATIONAL, INC.
800 Capital Square
400 Locust Street
Des Moines, IA 50309
1-800-247-6803

007690-01568560

PATENT

Attorney Docket No. 1121

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of U.S. Application Serial No. 60/144,112
filed July 16, 1999, which is herein incorporated by reference.

TECHNICAL FIELD

The present invention relates generally to plant molecular biology. More
10 specifically, it relates to nucleic acids and methods for modulating their expression in
plants.

BACKGROUND OF THE INVENTION

Homologous recombination is a very important mechanism by which all living
15 organisms exchange genetic information, thereby generating genetic diversity.
Moreover, this mechanism also allows organisms to maintain genetic stability by
protecting their genome against physico-chemical or environmental insults. Homologous
recombination is a very complex process involving several well-defined biochemical
steps, which are catalyzed by the concerted action of many cellular proteins. For
20 example, in *E.coli*, dozens of genes and their cognate protein products have been
implicated in homologous recombination (Kowalczykowski, S., Dixon, D., Eggleston,
A., Lauder, S. and Rehrauer, W., *Microb. Rev.* 58: 401-465, 1994). The picture is even
more complex in eukaryotic organisms.

Despite the complexity of the process, recent genetic, biochemical, and molecular
25 studies have revealed many mechanistic similarities in homologous recombination of
prokaryotic and eukaryotic organisms (Camerini-Otero, D. and Hsieh, P., *Ann. Rev.*
Biochem. 29: 509-552, 1995). For the sake of understanding, this pathway can be
divided into four discrete biochemical steps: 1) initiation 2) homologous pairing and
DNA strand exchange 3) branch migration and 4) resolution. In bacteria, the action of
30 various proteins such as those encoded by the genes *recBCD*, *recE*, *recQ* and *recJ*,
initiate the recombination process, step 1, by generating single stranded DNA. The
bacterial RecA protein, the product of the *recA* gene, catalyzes the next step of homology
search, pairing, and strand exchange, whereas in eukaryotes, members of the RAD51

gene family are implicated in this process. The final step, resolution of the Holliday junction, is attributed to the actions of bacterial RuvC.

The third step in the process is branch migration, also known as heteroduplex extension. A complex of two proteins, RuvA and RuvB catalyzes this reaction.

- 5 Extensive characterization of these proteins and their role of in this reaction has been performed in *E. coli* (West S.C., *Ann. Rev. Gen.* 31: 213-244, 1997). The product of the *ruvA* gene, the 22kDa RuvA protein, exists as a stable tetramer in solution and specifically recognizes and binds to the Holliday junction with very high affinity. This binding is structure specific, independent of the DNA sequence, and Mg^{2+} dependent.
- 10 Binding of RuvA to the Holliday junction by itself is not sufficient to cause branch migration either *in vitro* or *in vivo*. Presence of the second component, RuvB, is required.

- RuvB is the product of the bacterial gene *ruvB*. This protein has two NTP binding motifs, known as Walker A and Walker B boxes, as well as other structural motifs common to DNA helicases (West S.C., *Ann. Rev. Gen.* 31: 213-244, 1997). In the absence of metal ions, RuvB exists as a monomer or dimer in solution. However, the functional form of this enzyme is thought to be a hexamer. Two hexameric RuvB units bind to DNA in a symmetrical manner to form a ring, similar to the hexameric ring formed by other DNA helicases. Binding of ATP or DNA to RuvB is Mg^{2+} dependent,
- 15 such that at low concentration of Mg^{2+} , RuvB has very low affinity for DNA and does not hydrolyze ATP. Raising Mg^{2+} concentration $>20mM$ increases RuvB's affinity for DNA as well as its ATPase activity. Circular duplex DNA also stimulates the ATPase activity. RuvA also increases the affinity of RuvB for DNA. RuvB alone is sufficient to promote branch migration *in vitro*. However, a RuvAB complex functions much
- 20 more robustly, and requires less Mg^{2+} . Thus, RuvB participates in one of the rate limiting steps in homologous recombination in all living organisms.

- Recently, eukaryotic homologues of bacterial RuvB have been cloned and characterized. For example, Kanemaki *et al.* isolated a 49kDa TBP interacting protein (Tip49) from rat liver. The full-length cDNA of Tip49 revealed its strong homology to
- 30 bacterial RuvB protein (Kanemaki, M., Makino, Y., Yoshida, T., Kishimoto, T., Koga, A., Yamamoto, K., Moncollin, V., Egly, J-M., Muramatsu, M. and Tamura, T., *Arch. Biochem. Biophys.*, 235: 64-68, 1997). The same scientists also reported the cloning of human Tip49 (Makino, Y., Mimori, T., Koike, C., Kanemaki, M., Kurokawa Y.,

Inoue, S., Kishimoto, T., and Tamura, T., *Biochem. Biophys. Res. Commun.*, 245: 819-823, 1998). Similarly, cDNA for a human protein called RuvBL1 has been isolated employing the small (14kDa) subunit of human Replication Protein A, a hetero-trimeric protein involved in DNA replication, recombination and repair, as bait in the yeast two-hybrid assays. Two yeast homologues, scRuvBL1 and ScRuvBL2, have also been identified in the yeast genome database. Gene knockout experiments in yeast indicate that scRuvBL1 is essential for growth (Qiu, X., Lin, Y., Thome, K., Pian, P., Schlegel, B., Weremowicz, S., Parvin, J. and Dutta, A., *J. Biol. Chem.* 273: 27786-27793, 1998).

Due to the involvement of RuvB in homologous recombination, modulating RuvB expression levels provides the means to modulate the efficiency with which nucleic acids of interest are incorporated into the genomes of a target plant cell. Control of these processes has important implications in the creation of novel recombinantly engineered crops such as maize. The present invention provides this and other advantages.

SUMMARY OF THE INVENTION

Generally, it is the object of the present invention to provide nucleic acids and proteins relating to maize RuvB. It is an object of the present invention to provide: 1) antigenic fragments of the proteins of the present invention; 2) transgenic plants comprising the nucleic acids of the present invention; 3) methods for modulating, in a transgenic plant, the expression of the nucleic acids of the present invention.

Therefore, in one aspect, the present invention relates to an isolated nucleic acid comprising a member selected from the group consisting of (a) a polynucleotide having a specified sequence identity to a polynucleotide encoding a polypeptide of the present invention; (b) a polynucleotide which is complementary to the polynucleotide of (a); and, (c) a polynucleotide comprising a specified number of contiguous nucleotides from a polynucleotide of (a) or (b). The isolated nucleic acid can be DNA.

In another aspect, the present invention relates to recombinant expression cassettes, comprising a nucleic acid of the present invention operably linked to a promoter.

In another aspect, the present invention is directed to a host cell into which has been introduced the recombinant expression cassette.

In a further aspect, the present invention relates to an isolated protein comprising a polypeptide having a specified number of contiguous amino acids encoded by an isolated nucleic acid of the present invention.

In another aspect, the present invention relates to an isolated nucleic acid comprising a polynucleotide of specified length which selectively hybridizes under stringent conditions to a polynucleotide of the present invention, or a complement thereof. In some embodiments, the isolated nucleic acid is operably linked to a promoter.

In another aspect, the present invention relates to a recombinant expression cassette comprising a nucleic acid amplified from a library as referred to *supra*, wherein the nucleic acid is operably linked to a promoter. In some embodiments, the present invention relates to a host cell transfected with this recombinant expression cassette. In some embodiments, the present invention relates to a protein of the present invention that is produced from this host cell.

In yet another aspect, the present invention relates to a transgenic plant comprising a recombinant expression cassette comprising a plant promoter operably linked to any of the isolated nucleic acids of the present invention. The present invention also provides transgenic seed from the transgenic plant.

20 **Definitions**

Units, prefixes, and symbols may be denoted in their SI accepted form. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. Numeric ranges are inclusive of the numbers defining the range and include each integer within the defined range. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. Unless otherwise provided for, software, electrical, and electronics terms as used herein are as defined in The New IEEE Standard Dictionary of Electrical and Electronics Terms (5th edition, 1993). The terms defined below are more fully defined by reference to the specification as a whole.

By "amplified" is meant the construction of multiple copies of a nucleic acid sequence or multiple copies complementary to the nucleic acid sequence using at least

03589510.060700

one of the nucleic acid sequences as a template. Amplification systems include the polymerase chain reaction (PCR) system, ligase chain reaction (LCR) system, nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario), Q-Beta Replicase systems, transcription-based amplification system (TAS), and strand displacement amplification (SDA). See, e.g., *Diagnostic Molecular Microbiology: Principles and Applications*, D. H. Persing *et al.*, Ed., American Society for Microbiology, Washington, D.C. (1993). The product of amplification is termed an amplicon.

The term "antibody" includes reference to antigen binding forms of antibodies (e.g., Fab, F(ab)₂). The term "antibody" frequently refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof which specifically bind and recognize an analyte (antigen). However, while various antibody fragments can be defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments such as single chain Fv, chimeric antibodies (i.e., comprising constant and variable regions from different species), humanized antibodies (i.e., comprising a complementarity determining region (CDR) from a non-human source) and heteroconjugate antibodies (e.g., bispecific antibodies).

The term "antigen" includes reference to a substance to which an antibody can be generated and/or to which the antibody is specifically immunoreactive. The specific immunoreactive sites within the antigen are known as epitopes or antigenic determinants. These epitopes can be a linear array of monomers in a polymeric composition - such as amino acids in a protein - or consist of or comprise a more complex secondary or tertiary structure. Those of skill will recognize that all immunogens (i.e., substances capable of eliciting an immune response) are antigens; however some antigens, such as haptens, are not immunogens but may be made immunogenic by coupling to a carrier molecule. An antibody immunologically reactive with a particular antigen can be generated *in vivo* or by recombinant methods such as selection of libraries of recombinant antibodies in phage or similar vectors. See, e.g., Huse *et al.*, *Science* 246: 1275-1281 (1989); and Ward, *et al.*, *Nature* 341: 544-546 (1989); and Vaughan *et al.*, *Nature Biotech.* 14: 309-314 (1996).

09589510-060700

As used herein, "antisense orientation" includes reference to a duplex polynucleotide sequence that is operably linked to a promoter in an orientation where the antisense strand is transcribed. The antisense strand is sufficiently complementary to an endogenous transcription product such that translation of the endogenous transcription product is often inhibited.

As used herein, "chromosomal region" includes reference to a length of a chromosome that may be measured by reference to the linear segment of DNA that it comprises. The chromosomal region can be defined by reference to two unique DNA sequences, i.e., markers.

The term "conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or conservatively modified variants of the amino acid sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations" and represent one species of conservatively modified variation. Every nucleic acid sequence herein that encodes a polypeptide also, by reference to the genetic code, describes every possible silent variation of the nucleic acid. One of ordinary skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine; and UGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide of the present invention is implicit in each described polypeptide sequence and is within the scope of the present invention.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Thus, any number of amino acid residues selected from the group of integers consisting of from 1 to 15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 10

09589510-060700

alterations can be made. Conservatively modified variants typically provide similar biological activity as the unmodified polypeptide sequence from which they are derived. For example, substrate specificity, enzyme activity, or ligand/receptor binding is generally at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the native protein for its native substrate. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
 - 2) Aspartic acid (D), Glutamic acid (E);
 - 3) Asparagine (N), Glutamine (Q);
 - 4) Arginine (R), Lysine (K);
 - 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
 - 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
- See also, Creighton (1984) *Proteins* W.H. Freeman and Company.

By "encoding" or "encoded", with respect to a specified nucleic acid, is meant comprising the information for translation into the specified protein. A nucleic acid encoding a protein may comprise non-translated sequences (e.g., introns) within translated regions of the nucleic acid, or may lack such intervening non-translated sequences (e.g., as in cDNA). The information by which a protein is encoded is specified by the use of codons. Typically, the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code. However, variants of the universal code, such as are present in some plant, animal, and fungal mitochondria, the bacterium *Mycoplasma capricolum*, or the ciliate *Macronucleus*, may be used when the nucleic acid is expressed therein.

When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences of the intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray

et al. Nucl. Acids Res. 17: 477-498 (1989)). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray *et al.*, *supra*.

As used herein "full-length sequence" in reference to a specified polynucleotide or its encoded protein means having the entire amino acid sequence of, a native (non-synthetic), endogenous, biologically active form of the specified protein. Methods to determine whether a sequence is full-length are well known in the art including such exemplary techniques as northern or western blots, primer extension, S1 protection, and ribonuclease protection. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997). Comparison to known full-length homologous (orthologous and/or paralogous) sequences can also be used to identify full-length sequences of the present invention. Additionally, consensus sequences typically present at the 5' and 3' untranslated regions of mRNA aid in the identification of a polynucleotide as full-length. For example, the consensus sequence ANNNNAAUGG, where the underlined codon represents the N-terminal methionine, aids in determining whether the polynucleotide has a complete 5' end. Consensus sequences at the 3' end, such as polyadenylation sequences, aid in determining whether the polynucleotide has a complete 3' end.

As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, one or both are substantially modified from their original form. A heterologous protein may originate from a foreign species or, if from the same species, is substantially modified from its original form by deliberate human intervention.

By "host cell" is meant a cell which contains a vector and supports the replication and/or expression of the vector. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells. Preferably, host cells are monocotyledonous or dicotyledonous plant cells. A particularly preferred monocotyledonous host cell is a maize host cell.

09589510-060700

The term "hybridization complex" includes reference to a duplex nucleic acid structure formed by two single-stranded nucleic acid sequences selectively hybridized with each other.

By "immunologically reactive conditions" or "immunoreactive conditions" is meant conditions which allow an antibody, reactive to a particular epitope, to bind to that epitope to a detectably greater degree (e.g., at least 2-fold over background) than the antibody binds to substantially any other epitopes in a reaction mixture comprising the particular epitope. Immunologically reactive conditions are dependent upon the format of the antibody binding reaction and typically are those utilized in immunoassay protocols. See Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions.

The term "introduced" in the context of inserting a nucleic acid into a cell, means "transfection" or "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plasmid or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

The terms "isolated" refers to material, such as a nucleic acid or a protein, which is: (1) substantially or essentially free from components that normally accompany or interact with it as found in its naturally occurring environment. The isolated material optionally comprises material not found with the material in its natural environment; or (2) if the material is in its natural environment, the material has been synthetically (non-naturally) altered by deliberate human intervention to a composition and/or placed at a location in the cell (e.g., genome or subcellular organelle) not native to a material found in that environment. The alteration to yield the synthetic material can be performed on the material within or removed from its natural state. For example, a naturally occurring nucleic acid becomes an isolated nucleic acid if it is altered, or if it is transcribed from DNA which has been altered, by means of human intervention performed within the cell from which it originates. See, e.g., Compounds and Methods for Site Directed Mutagenesis in Eukaryotic Cells, Kmiec, U.S. Patent No. 5,565,350; *In Vivo* Homologous Sequence Targeting in Eukaryotic Cells; Zarling *et al.*, PCT/US93/03868. Likewise, a naturally occurring nucleic acid (e.g., a promoter) becomes isolated if it is

introduced by non-naturally occurring means to a locus of the genome not native to that nucleic acid. Nucleic acids which are "isolated" as defined herein, are also referred to as "heterologous" nucleic acids.

Unless otherwise stated, the term "maize RuvB nucleic acid" is a nucleic acid of the present invention and means a nucleic acid comprising a polynucleotide of the present invention (a "maize RuvB polynucleotide") encoding a maize RuvB polypeptide. A "maize RuvB gene" is a gene of the present invention and refers to a heterologous genomic form of a full-length maize RuvB polynucleotide.

As used herein, "localized within the chromosomal region defined by and including" with respect to particular markers includes reference to a contiguous length of a chromosome delimited by and including the stated markers.

As used herein, "marker" includes reference to a locus on a chromosome that serves to identify a unique position on the chromosome. A "polymorphic marker" includes reference to a marker which appears in multiple forms (alleles) such that different forms of the marker, when they are present in a homologous pair, allow transmission of each of the chromosomes of that pair to be followed. A genotype may be defined by use of one or a plurality of markers.

As used herein, "nucleic acid" includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g., peptide nucleic acids).

By "nucleic acid library" is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook *et al.*, *Molecular Cloning - A Laboratory Manual*, 2nd ed., Vol. 1-3 (1989); and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994).

09589510-060700

As used herein "operably linked" includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are
5 contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

As used herein, the term "plant" includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. Plant cell, as used herein includes, without limitation, seeds, suspension cultures, embryos,
10 meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. A particularly preferred plant is *Zea mays*.

As used herein, "polynucleotide" includes reference to a deoxyribopolynucleotide, ribopolynucleotide, or analogs thereof that have the essential nature of a natural ribonucleotide in that they hybridize, under stringent hybridization conditions, to substantially the same nucleotide sequence as naturally occurring nucleotides and/or allow translation into the same amino acid(s) as the naturally
20 occurring nucleotide(s). A polynucleotide can be full-length or a subsequence of a native or heterologous structural or regulatory gene. Unless otherwise indicated, the term includes reference to the specified sequence as well as the complementary sequence thereof. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs
25 comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified
30 forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including among other things, simple and complex cells.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in

09589510.060700

which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The essential nature of such analogues of naturally occurring amino acids is that, when incorporated into a protein, that protein is specifically reactive to antibodies elicited to the same protein but consisting entirely of naturally occurring amino acids. The terms "polypeptide", "peptide" and "protein" are also inclusive of modifications including, but not limited to, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation. It will be appreciated, as is well known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Further, this invention contemplates the use of both the methionine-containing and the methionine-less amino terminal variants of the protein of the invention.

As used herein "promoter" includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells whether or not its origin is a plant cell. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria which comprise genes expressed in plant cells such *Agrobacterium* or *Rhizobium*. Examples of promoters under developmental control include promoters that preferentially initiate transcription in certain tissues, such as leaves, roots, or seeds. Such promoters are referred to as "tissue preferred". Promoters which initiate transcription only in certain tissue are referred to as "tissue specific". A "cell type" specific promoter primarily drives expression in certain cell types in one or more organs, for example, vascular cells in roots or leaves. An "inducible" or "repressible" promoter is a promoter which is under environmental control. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions or the presence of light. Tissue specific, tissue preferred, cell type specific, and inducible promoters constitute the class of "non-constitutive" promoters. A

09589510.060700

"constitutive" promoter is a promoter which is active under most environmental conditions.

The term "maize RuvB polypeptide" is a polypeptide of the present invention and refers to one or more amino acid sequences, in glycosylated or non-glycosylated form.

- 5 The term is also inclusive of fragments, variants, homologs, alleles or precursors (e.g., preproteins or proproteins) thereof. A "maize RuvB protein" is a protein of the present invention and comprises a maize RuvB polypeptide.

- As used herein "recombinant" includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under-expressed or not expressed at all as a result of deliberate human intervention. The term "recombinant" as used herein does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation/transduction/transposition) such as those occurring without deliberate human intervention.
- 10
- 15

- As used herein, a "recombinant expression cassette" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plasmid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid to be transcribed, and a promoter.
- 20

- The term "residue" or "amino acid residue" or "amino acid" are used interchangeably herein to refer to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively "protein"). The amino acid may be a naturally occurring amino acid and, unless otherwise limited, may encompass non-natural analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.
- 25

- The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than its hybridization to non-target nucleic acid sequences and to the substantial exclusion of
- 30

09589510.060700

non-target nucleic acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, preferably 90% sequence identity, and most preferably 100% sequence identity (i.e., complementary) with each other.

The term "specifically reactive", includes reference to a binding reaction between an antibody and a protein having an epitope recognized by the antigen binding site of the antibody. This binding reaction is determinative of the presence of a protein having the recognized epitope amongst the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to an analyte having the recognized epitope to a substantially greater degree (e.g., at least 2-fold over background) than to substantially all analytes lacking the epitope which are present in the sample.

Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the polypeptides of the present invention can be selected from to obtain antibodies specifically reactive with polypeptides of the present invention. The proteins used as immunogens can be in native conformation or denatured so as to provide a linear epitope.

A variety of immunoassay formats may be used to select antibodies specifically reactive with a particular protein (or other analyte). For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York (1988), for a description of immunoassay formats and conditions that can be used to determine selective reactivity.

The term "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which a probe will hybridize to its target sequence, to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to the probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, optionally less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides) and at least about 60°C for long probes (*e.g.*, greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl, *Anal. Biochem.*, 138:267-284 (1984): $T_m = 81.5 ^\circ\text{C} + 16.6 (\log M) + 0.41 (\%GC) - 0.61 (\% \text{ form}) - 500/L$; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1 °C for each 1% of mismatching; thus, T_m , hybridization and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with $\geq 90\%$ identity are sought, the T_m can be decreased 10 °C. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4 °C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10 °C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20 °C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m , those of

ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45 °C (aqueous solution) or 32 °C (formamide solution) it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993); and *Current Protocols in Molecular Biology*, Chapter 2, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

As used herein, "transgenic plant" includes reference to a plant which comprises within its genome a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette. "Transgenic" is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.

As used herein, "vector" includes reference to a nucleic acid used in transfection of a host cell and into which can be inserted a polynucleotide. Vectors are often replicons. Expression vectors permit transcription of a nucleic acid inserted therein.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a

(b) As used herein, "comparison window" includes reference to a contiguous and specified segment of a polynucleotide/polypeptide sequence, wherein the

Methods of alignment of sequences for comparison are well-known in the art.

The BLAST family of programs which can be used for database similarity searches includes: BLASTN for nucleotide query sequences against nucleotide database sequences; BLASTX for nucleotide query sequences against protein database sequences; BLASTP for protein query sequences against protein database sequences; TBLASTN for protein query sequences against nucleotide database sequences; and TBLASTX for nucleotide query sequences against nucleotide database sequences. See, *Current*

The BLAST family of programs which can be used for database similarity searches includes: BLASTN for nucleotide query sequences against nucleotide database sequences; BLASTX for nucleotide query sequences against protein database sequences; 30 BLASTP for protein query sequences against protein database sequences; TBLASTN for protein query sequences against nucleotide database sequences; and TBLASTX for nucleotide query sequences against nucleotide database sequences. See, *Current*

Protocols in Molecular Biology, Chapter 19, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995).

Software for performing BLAST analyses is publicly available, e.g., through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold. These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W , T , and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, $M=5$, $N=-4$, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5877 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.

BLAST searches assume that proteins can be modeled as random sequences. However, many real proteins comprise regions of nonrandom sequences which may be homopolymeric tracts, short-period repeats, or regions enriched in one or more amino

00500510.060700

acids. Such low-complexity regions may be aligned between unrelated proteins even though other regions of the protein are entirely dissimilar. A number of low-complexity filter programs can be employed to reduce such low-complexity alignments. For example, the SEG (Wooten and Federhen, *Comput. Chem.*, 17:149-163 (1993)) and XNU (Claverie and States, *Comput. Chem.*, 17:191-201 (1993)) low-complexity filters can be employed alone or in combination.

GAP can also be used to compare a polynucleotide or polypeptide of the present invention with a reference sequence. GAP uses the algorithm of Needleman and Wunsch (*J. Mol. Biol.* 48: 443-453, 1970) to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of the length of the gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the Wisconsin Genetics Software Package for protein sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can each independently be: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 65 or greater.

GAP presents one member of the family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the Wisconsin Genetics Software

00589510-060700

Package is BLOSUM62 (see Henikoff & Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915).

Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using the BLAST 2.0 suite of programs using default parameters (Altschul *et al.*, *Nucleic Acids Res.* 25:3389-3402, 1997; Altschul *et al.*, *J. Mol. Bio.* 215: 403-410, 1990) or to the value obtained using the GAP program using default parameters (see the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wisconsin, USA).

(c) As used herein, "sequence identity" or "identity" in the context of two nucleic acid or polypeptide sequences includes reference to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g. charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences which differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well-known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., according to the algorithm of Meyers and Miller, *Computer Applic. Biol. Sci.*, 4: 11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California, USA).

(d) As used herein, "percentage of sequence identity" means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The

09589510.060700

percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

(e) (i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. However, nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This may occur, *e.g.*, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is that the polypeptide which the first nucleic acid encodes is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e) (ii) The terms "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window.

Optionally, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970). An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides which are "substantially similar" share sequences as noted above

002990.0156560

except that residue positions which are not identical may differ by conservative amino acid changes.

DETAILED DESCRIPTION OF THE INVENTION

5

Overview

The present invention provides, among other things, compositions and methods for modulating (i.e., increasing or decreasing) the level of polynucleotides and polypeptides of the present invention in plants. In particular, the polynucleotides and polypeptides of the present invention can be expressed temporally or spatially, e.g., at developmental stages, in tissues, and/or in quantities, which are uncharacteristic of non-recombinantly engineered plants. Thus, the present invention provides utility in such exemplary applications as in the control of homologous recombination efficiency or transformation efficiency in plants.

15 The present invention also provides isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a gene of the present invention to use as probes or amplification primers in the detection, quantitation, or isolation of gene transcripts. For example, isolated nucleic acids of the present invention can be used as probes in detecting deficiencies in the level of mRNA in screenings for desired transgenic plants, for detecting mutations in the gene (e.g., substitutions, deletions, or additions), for monitoring upregulation of expression or changes in enzyme activity in screening assays of compounds, for detection of any number of allelic variants (polymorphisms), orthologs, or paralogs of the gene, or for site directed mutagenesis in eukaryotic cells (see, e.g., U.S. Patent No. 5,565,350). The isolated nucleic acids of the present invention can also be used for recombinant expression of their encoded polypeptides, or for use as immunogens in the preparation and/or screening of antibodies. The isolated nucleic acids of the present invention can also be employed for use in sense or antisense suppression of one or more genes of the present invention in a host cell, tissue, or plant. Attachment of chemical agents which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids of the present invention can also be used to modulate transcription or translation.

30 The present invention also provides isolated proteins comprising a polypeptide of the present invention (e.g., preproenzyme, proenzyme, or enzymes). The present

0050510.060700

invention also provides proteins comprising at least one epitope from a polypeptide of the present invention. The proteins of the present invention can be employed in assays for enzyme agonists or antagonists of enzyme function, or for use as immunogens or antigens to obtain antibodies specifically immunoreactive with a protein of the present invention. Such antibodies can be used in assays for expression levels, for identifying and/or isolating nucleic acids of the present invention from expression libraries, for identification of homologous polypeptides from other species, or for purification of polypeptides of the present invention.

The isolated nucleic acids and polypeptides of the present invention can be used over a broad range of plant types, particularly monocots such as the species of the family *Gramineae* including *Hordeum*, *Secale*, *Triticum*, *Sorghum* (e.g., *S. bicolor*) and *Zea* (e.g., *Z. mays*). The isolated nucleic acid and proteins of the present invention can also be used in species from the genera: *Cucurbita*, *Rosa*, *Vitis*, *Juglans*, *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Datura*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Ciahorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*, *Heterocallis*, *Nemesis*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browaalia*, *Glycine*, *Pisum*, *Phaseolus*, *Lolium*, *Oryza*, and *Avena*.

Nucleic Acids

The present invention provides, among other things, isolated nucleic acids of RNA, DNA, and analogs and/or chimeras thereof, comprising a polynucleotide of the present invention.

A polynucleotide of the present invention is inclusive of:

(a) a polynucleotide encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10 and conservatively modified and polymorphic variants thereof, including exemplary polynucleotides of SEQ ID NOS: 1, 3, 5, 7, 9; polynucleotide sequences of the invention also include the maize R2 polynucleotide sequences as contained in plasmids deposited with American Type Culture Collection (ATCC) and assigned Accession Number 207193.

(b) a polynucleotide which is the product of amplification from a *Zea mays* nucleic acid library using primer pairs which selectively hybridize under stringent

09585510-060700

conditions to loci within a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, or the sequences as contained in the ATCC deposit assigned Accession Number 207193; wherein the polynucleotide has substantial sequence identity to a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9; or
5 the sequences as contained in the ATCC deposit assigned Accession Number 207193.

(c) a polynucleotide which selectively hybridizes to a polynucleotide of (a) or (b);

(d) a polynucleotide having a specified sequence identity with polynucleotides of (a), (b), or (c);

(e) a polynucleotide encoding a protein having a specified number of contiguous
10 amino acids from a prototype polypeptide, wherein the protein is specifically recognized by antisera elicited by presentation of the protein and wherein the protein does not detectably immunoreact to antisera which has been fully immunosorbed with the protein;

(f) complementary sequences of polynucleotides of (a), (b), (c), (d), or (e); and

(g) a polynucleotide comprising at least a specific number of contiguous
15 nucleotides from a polynucleotide of (a), (b), (c), (d), (e), or (f).

The polynucleotides of SEQ ID NOS: 1, 3, 5, 7, 9 are contained in plasmids deposited with American Type Culture Collection (ATCC) on April 6, 1999 and assigned Accession Number 207193. American Type Culture Collection is located at 10801 University Blvd., Manassas, VA 20110-2209.

20 The ATCC deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The deposit is provided as a convenience to those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. Section 112.

25 *A. Polynucleotides Encoding A Polypeptide of the Present Invention or Conservatively Modified or Polymorphic Variants Thereof*

As indicated in (a), above, the present invention provides isolated nucleic acids comprising a polynucleotide of the present invention, wherein the polynucleotide encodes a polypeptide of the present invention, or conservatively modified or polymorphic
30 variants thereof. Accordingly, the present invention includes polynucleotides of SEQ ID NOS: 1, 3, 5, 7, 9, and the sequences as contained in the ATCC deposit assigned Accession Number 207193, and silent variations of polynucleotides encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10. The present invention further provides

09589510.060700

isolated nucleic acids comprising polynucleotides encoding conservatively modified variants of a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10. Conservatively modified variants can be used to generate or select antibodies immunoreactive to the non-variant polypeptide. Additionally, the present invention further provides isolated nucleic acids comprising polynucleotides encoding one or more allelic (polymorphic) variants of polypeptides/polynucleotides. Polymorphic variants are frequently used to follow segregation of chromosomal regions in, for example, marker assisted selection methods for crop improvement.

10 *B. Polynucleotides Amplified from a Zea mays Nucleic Acid Library*

As indicated in (b), above, the present invention provides an isolated nucleic acid comprising a polynucleotide of the present invention, wherein the polynucleotides are amplified from a *Zea mays* nucleic acid library. *Zea mays* lines B73, PHRE1, A632, BMS-P2#10, W23, and Mo17 are known and publicly available. Other publicly known and available maize lines can be obtained from the Maize Genetics Cooperation (Urbana, IL). The nucleic acid library may be a cDNA library, a genomic library, or a library generally constructed from nuclear transcripts at any stage of intron processing. cDNA libraries can be normalized to increase the representation of relatively rare cDNAs. In optional embodiments, the cDNA library is constructed using a full-length cDNA synthesis method. Examples of such methods include Oligo-Capping (Maruyama, K. and Sugano, S. *Gene* 138: 171-174, 1994), Biotinylated CAP Trapper (Carninci, P., Kvan, C., *et al. Genomics* 37: 327-336, 1996), and CAP Retention Procedure (Edery, E., Chu, L.L., *et al. Molecular and Cellular Biology* 15: 3363-3371, 1995). cDNA synthesis is often catalyzed at 50-55°C to prevent formation of RNA secondary structure. Examples of reverse transcriptases that are relatively stable at these temperatures are SUPERScript II Reverse Transcriptase (Life Technologies, Inc.), AMV Reverse Transcriptase (Boehringer Mannheim) and RETROAMP Reverse Transcriptase (Epicentre). Rapidly growing tissues, or rapidly dividing cells are preferably used as mRNA sources.

30 The present invention also provides subsequences of the polynucleotides of the present invention. A variety of subsequences can be obtained using primers which selectively hybridize under stringent conditions to at least two sites within a

09589510.060700

polynucleotide of the present invention, or to two sites within the nucleic acid which flank and comprise a polynucleotide of the present invention, or to a site within a polynucleotide of the present invention and a site within the nucleic acid which comprises it. Primers are chosen to selectively hybridize, under stringent hybridization
5 conditions, to a polynucleotide of the present invention. Generally, the primers are complementary to a subsequence of the target nucleic acid which they amplify. As those skilled in the art will appreciate, the sites to which the primer pairs will selectively hybridize are chosen such that a single contiguous nucleic acid can be formed under the desired amplification conditions.

10 In optional embodiments, the primers will be constructed so that they selectively hybridize under stringent conditions to a sequence (or its complement) within the target nucleic acid which comprises the codon encoding the carboxy or amino terminal amino acid residue (i.e., the 3' terminal coding region and 5' terminal coding region, respectively) of the polynucleotides of the present invention. Optionally within these
15 embodiments, the primers will be constructed to selectively hybridize entirely within the coding region of the target polynucleotide of the present invention such that the product of amplification of a cDNA target will consist of the coding region of that cDNA. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50
20 nucleotides in length. Those of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e., annealing) to a target sequence. A non-annealing sequence at the 5' end of a primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends of the amplicon.

The amplification products can be translated using expression systems well
25 known to those of skill in the art and as discussed, *infra*. The resulting translation products can be confirmed as polypeptides of the present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or verifying the presence of one or more linear epitopes which are specific to a polypeptide of the present invention. Methods for protein synthesis from PCR
30 derived templates are known in the art and available commercially. See, e.g., Amersham Life Sciences, Inc, Catalog '97, p.354.

Methods for obtaining 5' and/or 3' ends of a vector insert are well known in the art. See, e.g., RACE (Rapid Amplification of Complementary Ends) as described in

00539510-060700

- Frohman, M. A., in PCR Protocols: A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, Eds. (Academic Press, Inc., San Diego), pp. 28-38 (1990)); see also, U.S. Pat. No. 5,470,722, and *Current Protocols in Molecular Biology*, Unit 15.6, Ausubel, *et al.*, Eds, Greene Publishing and Wiley-Interscience, New York (1995); Frohman and Martin, *Techniques* 1:165 (1989).

C. Polynucleotides Which Selectively Hybridize to a Polynucleotide of (A) or (B)

- As indicated in (c), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides selectively hybridize, under selective hybridization conditions, to a polynucleotide of sections (A) or (B) as discussed above. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and/or quantifying nucleic acids comprising the polynucleotides of (A) or (B). For example, polynucleotides of the present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library.
- In some embodiments, the polynucleotides are genomic or cDNA sequences isolated or otherwise complementary to a cDNA from a dicot or monocot nucleic acid library. Exemplary species of monocots and dicots include, but are not limited to: corn, canola, soybean, cotton, wheat, sorghum, sunflower, oats, sugar cane, millet, barley, and rice. Optionally, the cDNA library comprises at least 80% full-length sequences, preferably at least 85% or 90% full-length sequences, and more preferably at least 95% full-length sequences. The cDNA libraries can be normalized to increase the representation of rare sequences. Low stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. Low stringency conditions allow selective hybridization of sequences having about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

- D. Polynucleotides Having a Specific Sequence Identity with the Polynucleotides of (A), (B) or (C)*

As indicated in (d), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides have a specified identity at the nucleotide level to a polynucleotide as disclosed above in

sections (A), (B), or (C), above. The percentage of identity to a reference sequence is at least 60% and, rounded upwards to the nearest integer, can be expressed as an integer selected from the group of integers consisting of from 60 to 99. Thus, for example, the percentage of identity to a reference sequence can be at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

Optionally, the polynucleotides of this embodiment will encode a polypeptide that will share an epitope with a polypeptide encoded by the polynucleotides of sections (A), (B), or (C). Thus, these polynucleotides encode a first polypeptide which elicits production of antisera comprising antibodies which are specifically reactive to a second polypeptide encoded by a polynucleotide of (A), (B), or (C). However, the first polypeptide does not bind to antisera raised against itself when the antisera has been fully immunosorbed with the first polypeptide. Hence, the polynucleotides of this embodiment can be used to generate antibodies for use in, for example, the screening of expression libraries for nucleic acids comprising polynucleotides of (A), (B), or (C), or for purification of, or in immunoassays for, polypeptides encoded by the polynucleotides of (A), (B), or (C). The polynucleotides of this embodiment embrace nucleic acid sequences which can be employed for selective hybridization to a polynucleotide encoding a polypeptide of the present invention.

Screening polypeptides for specific binding to antisera can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 5-100 amino acids long, and often from about 8 to 15 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains the nucleotide sequence encoding the particular displayed peptide sequence. Such methods are described in PCT patent publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278. Other systems for generating libraries of peptides have aspects of both *in vitro* chemical synthesis and recombinant methods. See, PCT Patent publication Nos. 92/05258, 92/14843, and 96/19256. See also, U.S. Patent Nos. 5,658,754; and

5,643,768. Peptide display libraries, vectors, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, CA).

E. Polynucleotides Encoding a Protein Having a Subsequence from a Prototype

5 *Polypeptide and is Cross-Reactive to the Prototype Polypeptide*

As indicated in (e), above, the present invention provides isolated nucleic acids comprising polynucleotides of the present invention, wherein the polynucleotides encode a protein having a subsequence of contiguous amino acids from a prototype polypeptide of the present invention such as are provided in (a), above. The length of contiguous
10 amino acids from the prototype polypeptide is selected from the group of integers consisting of from at least 10 to the number of amino acids within the prototype sequence. Thus, for example, the polynucleotide can encode a polypeptide having a subsequence having at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 100, contiguous amino acids from the prototype polypeptide. Further, the
15 number of such subsequences encoded by a polynucleotide of the instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

The proteins encoded by polynucleotides of this embodiment, when presented as
20 an immunogen, elicit the production of polyclonal antibodies which specifically bind to a prototype polypeptide such as but not limited to, a polypeptide encoded by the polynucleotide of (a) or (b), above. Generally, however, a protein encoded by a polynucleotide of this embodiment does not bind to antisera raised against the prototype polypeptide when the antisera has been fully immunosorbed with the prototype
25 polypeptide. Methods of making and assaying for antibody binding specificity/affinity are well known in the art. Exemplary immunoassay formats include ELISA, competitive immunoassays, radioimmunoassays, Western blots, indirect immunofluorescent assays and the like.

In a preferred assay method, fully immunosorbed and pooled antisera which is
30 elicited to the prototype polypeptide can be used in a competitive binding assay to test the protein. The concentration of the prototype polypeptide required to inhibit 50% of the binding of the antisera to the prototype polypeptide is determined. If the amount of the protein required to inhibit binding is less than twice the amount of the prototype

00589510-060700

protein, then the protein is said to specifically bind to the antisera elicited to the immunogen. Accordingly, the proteins of the present invention embrace allelic variants, conservatively modified variants, and minor recombinant modifications to a prototype polypeptide.

A polynucleotide of the present invention optionally encodes a protein having a molecular weight as the non-glycosylated protein within 20% of the molecular weight of the full-length non-glycosylated polypeptides of the present invention. Molecular weight can be readily determined by SDS-PAGE under reducing conditions. Optionally, the molecular weight is within 15% of a full length polypeptide of the present invention, more preferably within 10% or 5%, and most preferably within 3%, 2%, or 1% of a full length polypeptide of the present invention.

Optionally, the polynucleotides of this embodiment will encode a protein having a specific enzymatic activity at least 50%, 60%, 80%, or 90% of a cellular extract comprising the native, endogenous full-length polypeptide of the present invention.

Further, the proteins encoded by polynucleotides of this embodiment will optionally have a substantially similar affinity constant (K_m) and/or catalytic activity (i.e., the microscopic rate constant, k_{cat}) as the native endogenous, full-length protein. Those of skill in the art will recognize that k_{cat}/K_m value determines the specificity for competing substrates and is often referred to as the specificity constant. Proteins of this

embodiment can have a k_{cat}/K_m value at least 10% of a full-length polypeptide of the present invention as determined using the endogenous substrate of that polypeptide.

Optionally, the k_{cat}/K_m value will be at least 20%, 30%, 40%, 50%, and most preferably at least 60%, 70%, 80%, 90%, or 95% the k_{cat}/K_m value of the full-length polypeptide of the present invention. Determination of k_{cat} , K_m , and k_{cat}/K_m can be determined by any

number of means well known to those of skill in the art. For example, the initial rates (i.e., the first 5% or less of the reaction) can be determined using rapid mixing and sampling techniques (e.g., continuous-flow, stopped-flow, or rapid quenching techniques), flash photolysis, or relaxation methods (e.g., temperature jumps) in conjunction with such exemplary methods of measuring as spectrophotometry, spectrofluorimetry, nuclear magnetic resonance, or radioactive procedures. Kinetic values are conveniently obtained using a Lineweaver-Burk or Eadie-Hofstee plot.

F. Polynucleotides Complementary to the Polynucleotides of (A)-(E)

As indicated in (f), above, the present invention provides isolated nucleic acids comprising polynucleotides complementary to the polynucleotides of paragraphs A-E, above. As those of skill in the art will recognize, complementary sequences base-pair throughout the entirety of their length with the polynucleotides of sections (A)-(E) (i.e., have 100% sequence identity over their entire length). Complementary bases associate through hydrogen bonding in double stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

G. Polynucleotides Which are Subsequences of the Polynucleotides of (A)-(F)

As indicated in (g), above, the present invention provides isolated nucleic acids comprising polynucleotides which comprise at least 15 contiguous bases from the polynucleotides of sections (A) through (F) as discussed above. The length of the polynucleotide is given as an integer selected from the group consisting of from at least 15 to the length of the nucleic acid sequence from which the polynucleotide is a subsequence of. Thus, for example, polynucleotides of the present invention are inclusive of polynucleotides comprising at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, or 200 contiguous nucleotides in length from the polynucleotides of (A)-(F). Optionally, the number of such subsequences encoded by a polynucleotide of the instant embodiment can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5. The subsequences can be separated by any integer of nucleotides from 1 to the number of nucleotides in the sequence such as at least 5, 10, 15, 25, 50, 100, or 200 nucleotides.

The subsequences of the present invention can comprise structural characteristics of the sequence from which it is derived. Alternatively, the subsequences can lack certain structural characteristics of the larger sequence from which it is derived such as a poly (A) tail. Optionally, a subsequence from a polynucleotide encoding a polypeptide having at least one linear epitope in common with a prototype polypeptide sequence as provided in (a), above, may encode an epitope in common with the prototype sequence. Alternatively, the subsequence may not encode an epitope in common with the prototype sequence but can be used to isolate the larger sequence by, for example, nucleic acid hybridization with the sequence from which it's derived. Subsequences can be used to

modulate or detect gene expression by introducing into the subsequences compounds which bind, intercalate, cleave and/or crosslink to nucleic acids. Exemplary compounds include acridine, psoralen, phenanthroline, naphthoquinone, daunomycin or chloroethylaminoaryl conjugates.

5

Construction of Nucleic Acids

The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, (b) synthetic techniques, or combinations thereof. In some embodiments, the polynucleotides of the present invention will be cloned, amplified, or otherwise constructed from a monocot. In preferred embodiments the monocot is *Zea mays*.

The nucleic acids may conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences may be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins of the present invention. A polynucleotide of the present invention can be attached to a vector, adapter, or linker for cloning and/or expression of a polynucleotide of the present invention. Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Typically, the length of a nucleic acid of the present invention less the length of its polynucleotide of the present invention is less than 20 kilobase pairs, often less than 15 kb, and frequently less than 10 kb. Use of cloning vectors, expression vectors, adapters, and linkers is well known and extensively described in the art. For a description of various nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, CA); and, Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, IL).

30

A. Recombinant Methods for Constructing Nucleic Acids

The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from plant biological sources using

00569510-060700

- any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes which selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. While isolation of RNA, and
- 5 construction of cDNA and genomic libraries is well known to those of ordinary skill in the art, the following highlights some of the methods employed.

A1. mRNA Isolation and Purification

- Total RNA from plant cells comprises such nucleic acids as mitochondrial RNA,
- 10 chloroplastic RNA, rRNA, tRNA, hnRNA and mRNA. Total RNA preparation typically involves lysis of cells and removal of organelles and proteins, followed by precipitation of nucleic acids. Extraction of total RNA from plant cells can be accomplished by a variety of means. Frequently, extraction buffers include a strong detergent such as SDS and an organic denaturant such as guanidinium isothiocyanate,
- 15 guanidine hydrochloride or phenol. Following total RNA isolation, poly(A)⁺ mRNA is typically purified from the remainder RNA using oligo(dT) cellulose. Exemplary total RNA and mRNA isolation protocols are described in *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience,
- 20 New York (1995). Total RNA and mRNA isolation kits are commercially available from vendors such as Stratagene (La Jolla, CA), Clontech (Palo Alto, CA), Pharmacia (Piscataway, NJ), and 5'-3' (Paoli Inc., PA). See also, U.S. Patent Nos. 5,614,391; and, 5,459,253. The mRNA can be fractionated into populations with size ranges of about 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 kb. The cDNA synthesized for each of these
- 25 fractions can be size selected to the same size range as its mRNA prior to vector insertion. This method helps eliminate truncated cDNA formed by incompletely reverse transcribed mRNA.

A2. Construction of a cDNA Library

- 30 Construction of a cDNA library generally entails five steps. First, first strand cDNA synthesis is initiated from a poly(A)⁺ mRNA template using a poly(dT) primer or random hexanucleotides. Second, the resultant RNA-DNA hybrid is converted into double stranded cDNA, typically by reaction with a combination of RNase H and DNA

002090-0158950

polymerase I (or Klenow fragment). Third, the termini of the double stranded cDNA are ligated to adaptors. Ligation of the adaptors can produce cohesive ends for cloning. Fourth, size selection of the double stranded cDNA eliminates excess adaptors and primer fragments, and eliminates partial cDNA molecules due to degradation of mRNAs or the failure of reverse transcriptase to synthesize complete first strands. Fifth, the cDNAs are ligated into cloning vectors and packaged. cDNA synthesis protocols are well known to the skilled artisan and are described in such standard references as: *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); and, *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995). cDNA synthesis kits are available from a variety of commercial vendors such as Stratagene or Pharmacia.

A number of cDNA synthesis protocols have been described which provide substantially pure full-length cDNA libraries. Substantially pure full-length cDNA libraries are constructed to comprise at least 90%, and more preferably at least 93% or 95% full-length inserts amongst clones containing inserts. The length of insert in such libraries can be from 0 to 8, 9, 10, 11, 12, 13, or more kilobase pairs. Vectors to accommodate inserts of these sizes are known in the art and available commercially. See, e.g., Stratagene's lambda ZAP Express (cDNA cloning vector with 0 to 12 kb cloning capacity).

An exemplary method of constructing a greater than 95% pure full-length cDNA library is described by Carninci *et al.*, *Genomics*, 37:327-336 (1996). In that protocol, the cap-structure of eukaryotic mRNA is chemically labeled with biotin. By using streptavidin-coated magnetic beads, only the full-length first-strand cDNA/mRNA hybrids are selectively recovered after RNase I treatment. The method provides a high yield library with an unbiased representation of the starting mRNA population. Other methods for producing full-length libraries are known in the art. See, e.g., Edery *et al.*, *Mol. Cell Biol.*, 15(6):3363-3371 (1995); and, PCT Application WO 96/34981.

A3. Normalized or Subtracted cDNA Libraries

A non-normalized cDNA library represents the mRNA population of the tissue it was made from. Since unique clones are out-numbered by clones derived from highly expressed genes their isolation can be laborious. Normalization of a cDNA library is the process of creating a library in which each clone is more equally represented.

A number of approaches to normalize cDNA libraries are known in the art. One approach is based on hybridization to genomic DNA. The frequency of each hybridized cDNA in the resulting normalized library would be proportional to that of each corresponding gene in the genomic DNA. Another approach is based on kinetics. If cDNA reannealing follows second-order kinetics, rarer species anneal less rapidly and the remaining single-stranded fraction of cDNA becomes progressively more normalized during the course of the hybridization. Specific loss of any species of cDNA, regardless of its abundance, does not occur at any Cot value. Construction of normalized libraries is described in Ko, *Nucl. Acids. Res.*, 18(19):5705-5711 (1990); Patanjali *et al.*, *Proc. Natl. Acad. U.S.A.*, 88:1943-1947 (1991); U.S. Patents 5,482,685, and 5,637,685. In an exemplary method described by Soares *et al.*, normalization resulted in reduction of the abundance of clones from a range of four orders of magnitude to a narrow range of only 1 order of magnitude. *Proc. Natl. Acad. Sci. USA*, 91:9228-9232 (1994).

Subtracted cDNA libraries are another means to increase the proportion of less abundant cDNA species. In this procedure, cDNA prepared from one pool of mRNA is depleted of sequences present in a second pool of mRNA by hybridization. The cDNA:mRNA hybrids are removed and the remaining un-hybridized cDNA pool is enriched for sequences unique to that pool. See, Foote *et al.* in, *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed., Springer-Verlag, Berlin (1997); Kho and Zarbl, *Technique*, 3(2):58-63 (1991); Sive and St. John, *Nucl. Acids Res.*, 16(22):10937 (1988); *Current Protocols in Molecular Biology*, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience, New York (1995); and, Swaroop *et al.*, *Nucl. Acids Res.*, 19(8):1954 (1991). cDNA subtraction kits are commercially available. See, e.g., PCR-Select (Clontech, Palo Alto, CA).

A4. Construction of a Genomic Library

To construct genomic libraries, large segments of genomic DNA are generated by fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. Methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate molecular biological techniques and instructions sufficient to direct persons of skill through many construction, cloning, and screening methodologies are found in Sambrook, *et al.*, *Molecular Cloning: A*

09589510-060700

Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Vols. 1-3 (1989),
Methods in Enzymology, Vol. 152: *Guide to Molecular Cloning Techniques*, Berger
and Kimmel, Eds., San Diego: Academic Press, Inc. (1987), *Current Protocols in*
Molecular Biology, Ausubel, *et al.*, Eds., Greene Publishing and Wiley-Interscience,
New York (1995); *Plant Molecular Biology: A Laboratory Manual*, Clark, Ed.,
Springer-Verlag, Berlin (1997). Kits for construction of genomic libraries are also
commercially available.

A5. Nucleic Acid Screening and Isolation Methods

The cDNA or genomic library can be screened using a probe based upon the
sequence of a polynucleotide of the present invention such as those disclosed herein.
Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate
homologous genes in the same or different plant species. Those of skill in the art will
appreciate that various degrees of stringency of hybridization can be employed in the
assay; and either the hybridization or the wash medium can be stringent. As the
conditions for hybridization become more stringent, there must be a greater degree of
complementarity between the probe and the target for duplex formation to occur. The
degree of stringency can be controlled by temperature, ionic strength, pH and the
presence of a partially denaturing solvent such as formamide. For example, the
stringency of hybridization is conveniently varied by changing the polarity of the reactant
solution through manipulation of the concentration of formamide within the range of 0%
to 50%. The degree of complementarity (sequence identity) required for detectable
binding will vary in accordance with the stringency of the hybridization medium and/or
wash medium. The degree of complementarity will optimally be 100 percent; however,
it should be understood that minor sequence variations in the probes and primers may be
compensated for by reducing the stringency of the hybridization and/or wash medium.

The nucleic acids of interest can also be amplified from nucleic acid samples
using amplification techniques. For instance, polymerase chain reaction (PCR)
technology can be used to amplify the sequences of polynucleotides of the present
invention and related genes directly from genomic DNA or cDNA libraries. PCR and
other *in vitro* amplification methods may also be useful, for example, to clone nucleic
acid sequences that code for proteins to be expressed, to make nucleic acids to use as
probes for detecting the presence of the desired mRNA in samples, for nucleic acid

sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through *in vitro* amplification methods are found in Berger, Sambrook, and Ausubel, as well as Mullis *et al.*, U.S. Patent No. 4,683,202 (1987); and, *PCR Protocols A Guide to Methods and Applications*, Innis *et al.*, Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

PCR-based screening methods have also been described. Wilfinger *et al.* describe a PCR-based method in which the longest cDNA is identified in the first step so that incomplete clones can be eliminated from study. *BioTechniques*, 22(3): 481-486 (1997). In that method, a primer pair is synthesized with one primer annealing to the 5' end of the sense strand of the desired cDNA and the other primer to the vector. Clones are pooled to allow large-scale screening. By this procedure, the longest possible clone is identified amongst candidate clones. Further, the PCR product is used solely as a diagnostic for the presence of the desired cDNA and does not utilize the PCR product itself. Such methods are particularly effective in combination with a full-length cDNA construction methodology, above.

B. Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang *et al.*, *Meth. Enzymol.* 68: 90-99 (1979); the phosphodiester method of Brown *et al.*, *Meth. Enzymol.* 68: 109-151 (1979); the diethylphosphoramidite method of Beaucage *et al.*, *Tetra. Lett.* 22: 1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, *Tetra. Letts.* 22(20): 1859-1862 (1981), e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter *et al.*, *Nucleic Acids Res.*, 12: 6159-6168 (1984); and, the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single stranded oligonucleotide. This may be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill will recognize that while chemical synthesis of DNA is best employed for sequences of about 100 bases or less, longer sequences may be obtained by the ligation of shorter sequences.

09589510.060700

Recombinant Expression Cassettes

The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention. A nucleic acid sequence coding for the desired polypeptide of the present invention, for example a cDNA or a genomic sequence encoding a full length polypeptide of the present invention, can be used to construct a recombinant expression cassette which can be introduced into the desired host cell. A recombinant expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences which will direct the transcription of the polynucleotide in the intended host cell, such as tissues of a transformed plant.

For example, plant expression vectors may include (1) a cloned plant gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

A plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin 1 promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No. 5,683,439), the *Nos* promoter, the pEmu promoter, the rubisco promoter, the GRP1-8 promoter, and other transcription initiation regions from various plant genes known to those of skill. One exemplary promoter is the ubiquitin promoter, which can be used to drive expression of the present invention in embryos or embryogenic callus, particularly in maize.

Alternatively, the plant promoter can direct expression of a polynucleotide of the present invention in a specific tissue or may be otherwise under more precise environmental or developmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by

inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDk promoter which is inducible by light.

Examples of promoters under developmental control include promoters that initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. Exemplary promoters include the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051), glob-1 promoter, and gamma-zein promoter. The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue. Thus, in some embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in *Zea mays*, operably linked to a polynucleotide of the present invention. Promoters useful in these embodiments include the endogenous promoters driving expression of a polypeptide of the present invention.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous promoters can be altered *in vivo* by mutation, deletion, and/or substitution (see, Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene. Gene expression can be modulated under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition of the polypeptides of the present invention in plant cell. Thus, the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous (i.e., non-heterologous) form of a polynucleotide of the present invention.

Methods for identifying promoters with a particular expression pattern, in terms of, e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. See, e.g., *The Maize Handbook*, Chapters 114-115, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3rd edition, Chapter 6, Sprague and Dudley, Eds., American Society of Agronomy, Madison, Wisconsin (1988). A typical step in promoter isolation methods is identification of gene products that are expressed with some degree of specificity in the target tissue. Amongst the range of methodologies are: differential hybridization to cDNA libraries; subtractive hybridization; differential display; differential 2-D protein gel electrophoresis; DNA probe arrays; and isolation of proteins known to be expressed with some specificity in the target tissue. Such methods are well known to those of skill in the art. Commercially available products for identifying promoters are known in the art such as Clontech's (Palo Alto, CA) Universal GenomeWalker Kit.

For the protein-based methods, it is helpful to obtain the amino acid sequence for at least a portion of the identified protein, and then to use the protein sequence as the basis for preparing a nucleic acid that can be used as a probe to identify either genomic DNA directly, or preferably, to identify a cDNA clone from a library prepared from the target tissue. Once such a cDNA clone has been identified, that sequence can be used to identify the sequence at the 5' end of the transcript of the indicated gene. For differential hybridization, subtractive hybridization and differential display, the nucleic acid sequence identified as enriched in the target tissue is used to identify the sequence at the 5' end of the transcript of the indicated gene. Once such sequences are identified, starting either from protein sequences or nucleic acid sequences, any of these sequences identified as being from the gene transcript can be used to screen a genomic library prepared from the target organism. Methods for identifying and confirming the transcriptional start site are well known in the art.

In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each particular gene in one or more other tissues of the plant. One can identify a promoter with activity in the desired tissue or condition but that does not have activity in any other common tissue.

05589510.060700

10

15

25

30

An intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. Buchman and Berg, *Mol. Cell Biol.* 8: 4395-4405 (1988); Callis *et al.*, *Genes Dev.* 1: 1183-1200 (1987). Such intron enhancement of gene expression is typically greatest when placed near the 5' end of the transcription unit. Use of maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. See generally, *The Maize Handbook*, Chapter 116, Freeling and Walbot, Eds., Springer, New York (1994).

The vector comprising the sequences from a polynucleotide of the present invention will typically comprise a marker gene which confers a selectable phenotype on plant cells. Usually, the selectable marker gene will encode antibiotic resistance, with suitable genes including genes coding for resistance to the antibiotic spectinomycin (e.g., the aada gene), the streptomycin phosphotransferase (SPT) gene coding for streptomycin resistance, the neomycin phosphotransferase (NPTII) gene encoding kanamycin or geneticin resistance, the hygromycin phosphotransferase (HPT) gene coding for hygromycin resistance, genes coding for resistance to herbicides which act to inhibit the action of acetolactate synthase (ALS), in particular the sulfonylurea-type herbicides (e.g., the acetolactate synthase (ALS) gene containing mutations leading to such resistance in particular the S4 and/or Hra mutations), genes coding for resistance to herbicides which act to inhibit action of glutamine synthase, such as phosphinothricin or basta (e.g., the *bar* gene), or other such genes known in the art. The *bar* gene encodes resistance to the herbicide basta, the *nptII* gene encodes resistance to the antibiotics kanamycin and geneticin, and the ALS gene encodes resistance to the herbicide chlorsulfuron.

Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens* described by Rogers *et al.*, *Meth. in Enzymol.*, 153:253-277 (1987). These vectors are plant integrating vectors in that on transformation, the vectors integrate a portion of vector DNA into the genome of the host plant. Exemplary *A. tumefaciens* vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl *et al.*, *Gene*, 61:1-11 (1987) and Berger *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 86:8402-8406

05589510-060700

(1989). Another useful vector herein is plasmid pBI101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, CA).

A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable plant characteristics. Antisense technology can be conveniently used to inhibit gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti-sense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, e.g., Sheehy *et al.*, *Proc. Nat'l. Acad. Sci. (USA)* 85: 8805-8809 (1988); and Hiatt *et al.*, U.S. Patent No. 4,801,340.

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes see, Napoli *et al.*, *The Plant Cell* 2: 279-289 (1990) and U.S. Patent No. 5,034,323.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described in Haseloff *et al.*, *Nature* 334: 585-591 (1988).

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov, V. V., *et al.*, *Nucleic Acids Res* (1986) 14:4065-4076, describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. A report of similar work by the same group is that by Knorre, D. G., *et al.*, *Biochimie* (1985)

67:785-789. Iverson and Dervan also showed sequence-specific cleavage of single-stranded DNA mediated by incorporation of a modified nucleotide which was capable of activating cleavage (*J Am Chem Soc* (1987) 109:1241-1243). Meyer, R. B., *et al.*, *J Am Chem Soc* (1989) 111:8517-8519, effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides mediated by psoralen was disclosed by Lee, B. L., *et al.*, *Biochemistry* (1988) 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home, *et al.*, *J Am Chem Soc* (1990) 112:2435-2437. Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb and Matteucci, *J Am Chem Soc* (1986) 108:2764-2765; *Nucleic Acids Res* (1986) 14:7661-7674; Feteritz *et al.*, *J. Am. Chem. Soc.* 113:4000 (1991). Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and, 5,681,941.

Proteins

The isolated proteins of the present invention comprise a polypeptide having at least 10 amino acids encoded by any one of the polynucleotides of the present invention as discussed more fully, above, or polypeptides which are conservatively modified variants thereof. The proteins of the present invention or variants thereof can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers consisting of from 10 to the number of residues in a full-length polypeptide of the present invention. Optionally, this subsequence of contiguous amino acids is at least 15, 20, 25, 30, 35, or 40 amino acids in length, often at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

The present invention further provides a protein comprising a polypeptide having a specified sequence identity with a polypeptide of the present invention. The percentage of sequence identity is an integer selected from the group consisting of from 60 to 99. Exemplary sequence identity values include 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99%.

09589510.060700

As those of skill will appreciate, the present invention includes catalytically active polypeptides of the present invention (i.e., enzymes). Catalytically active polypeptides have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (k_{cat}/K_m) is optionally substantially similar to the native (non-synthetic), endogenous polypeptide. Typically, the K_m will be at least 30%, 40%, or 50%, that of the native (non-synthetic), endogenous polypeptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity (k_{cat}/K_m), are well known to those of skill in the art.

Generally, the proteins of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the present invention. Further, the proteins of the present invention will not bind to antisera raised against a polypeptide of the present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, *infra*. Thus, the proteins of the present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

Expression of Proteins in Host Cells

Using the nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacteria, yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the

DNA or cDNA to a promoter (which is either constitutive or regulatable), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (*e.g.*, poly His) placed on either terminus to create conveniently located purification sequences. Restriction sites or termination codons can also be introduced.

A. Expression in Prokaryotes

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., *Nature* 198:1056 (1977)), the tryptophan (trp) promoter system (Goeddel et al., *Nucleic Acids Res.* 8:4057 (1980)) and the lambda derived P L promoter and N-gene ribosome binding site (Shimatake et al., *Nature* 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA.

Expression systems for expressing a protein of the present invention are available using *Bacillus sp.* and *Salmonella* (Palva, *et al.*, *Gene* 22: 229-235 (1983); Mosbach, *et al.*, *Nature* 302: 543-545 (1983)).

5 *B. Expression in Eukaryotes*

A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a polynucleotide of the present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells, as discussed *infra*, are employed as expression systems for production of the proteins of the instant invention.

Synthesis of heterologous proteins in yeast is well known. Sherman, F., *et al.*, *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory (1982) is a well recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast for production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV *tk* promoter or *pgk* (phosphoglycerate kinase) promoter), an enhancer (Queen *et al.*, *Immunol. Rev.* 89: 49

09585510-060700

(1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (*e.g.*, an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type

5 Culture Collection.

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See, Schneider, *J. Embryol. Exp. Morphol.* 27: 353-365 (1987).

10 As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague,
15 *et al.*, *J. Virol.* 45: 773-781 (1983)). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M., Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector in *DNA Cloning Vol. II a Practical Approach*, D.M. Glover, Ed., IRL Press, Arlington, Virginia pp. 213-238 (1985).

20 Transfection/Transformation of Cells

The method of transformation/transfection is not critical to the instant invention; various methods of transformation or transfection are currently available. As newer methods are available to transform crops or other host cells they may be directly applied.

25 Accordingly, a wide variety of methods have been developed to insert a DNA sequence into the genome of a host cell to obtain the transcription and/or translation of the sequence to effect phenotypic changes in the organism. Thus, any method which provides for effective transformation/transfection may be employed.

30

A. Plant Transformation

A DNA sequence coding for the desired polypeptide of the present invention, for example a cDNA or a genomic sequence encoding a full length protein, will be used to

05589540-060700

construct a recombinant expression cassette which can be introduced into the desired plant.

Isolated nucleic acids of the present invention can be introduced into plants according to techniques known in the art. Generally, recombinant expression cassettes as described above and suitable for transformation of plant cells are prepared. The isolated nucleic acids of the present invention can then be used for transformation. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols may vary depending on the type of plant cell, i.e. monocot or dicot, targeted for transformation. Suitable methods of transforming plant cells include microinjection (Crossway *et al.* (1986) *Biotechniques* 4:320-334), electroporation (Riggs *et al.* (1986) *Proc. Natl. Acad. Sci. USA* 83:5602-5606, *Agrobacterium* mediated transformation (see for example, Zhao *et al.* U.S. Patent 5,981,840; Hinchey *et al.* (1988) *Biotechnology* 6:915-921), direct gene transfer (Paszowski *et al.* (1984) *EMBO J.* 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford *et al.* U.S. Patent 4,945,050; Tomes *et al.* "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment" In Gamborg and Phillips (Eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995); and McCabe *et al.* (1988) *Biotechnology* 6:923-926). Also see, Weissinger *et al.* (1988) *Annual Rev. Genet.* 22:421-477; Sanford *et al.* (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou *et al.* (1988) *Plant Physiol.* 87:671-674 (soybean); McCabe *et al.* (1988) *Bio/Technology* 6:923-926 (soybean); Datta *et al.* (1990) *Biotechnology* 8:736-740 (rice); Klein *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:4305-4309 (maize); Klein *et al.* (1988) *Biotechnology* 6:559-563 (maize); Tomes *et al.* "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment" In Gamborg and Phillips (Eds.) *Plant Cell, Tissue and Organ Culture: Fundamental Methods*, Springer-Verlag, Berlin (1995) (maize); Klein *et al.* (1988) *Plant Physiol.* 91:440-444 (maize) Fromm *et al.* (1990) *Biotechnology* 8:833-839 (maize); Hooykaas-Van Slogteren & Hooykaas (1984) *Nature (London)* 311:763-764; Bytebier *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:5345-5349 (Liliaceae); De Wet *et al.* (1985) In *The Experimental Manipulation of Ovule Tissues* ed. G.P. Chapman *et al.* pp. 197-209. Longman, NY (pollen); Kaeppler *et al.* (1990) *Plant Cell Reports* 9:415-418; and Kaeppler *et al.* (1992) *Theor. Appl. Genet.* 84:560-566 (whisker-mediated transformation); D'Halluin *et al.* (1992) *Plant Cell* 4:1495-1505

007090-0156836

(electroporation); LI *et al.* (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford (1995) *Annals of Botany* 75:745-750 (maize via *Agrobacterium tumefaciens*); all of which are herein incorporated by reference.

The cells which have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick *et al.* (1986) *Plant Cell Reports*, 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

B. Transfection of Prokaryotes, Lower Eukaryotes, and Animal Cells

Animal and lower eukaryotic (e.g., yeast) host cells are competent or rendered competent for transfection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, electroporation, biolistics, and micro-injection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art. Kuchler, R.J., *Biochemical Methods in Cell Culture and Virology*, Dowden, Hutchinson and Ross, Inc. (1977).

Synthesis of Proteins

The proteins of the present invention can be constructed using non-cellular synthetic methods. Solid phase synthesis of proteins of less than about 50 amino acids in length may be accomplished by attaching the C-terminal amino acid of the sequence to an insoluble support followed by sequential addition of the remaining amino acids in the sequence. Techniques for solid phase synthesis are described by Barany and Merrifield, Solid-Phase Peptide Synthesis, pp. 3-284 in *The Peptides: Analysis, Synthesis, Biology*. Vol. 2: *Special Methods in Peptide Synthesis, Part A.*; Merrifield, *et al.*, *J. Am. Chem. Soc.* 85: 2149-2156 (1963), and Stewart *et al.*, *Solid Phase Peptide Synthesis*, 2nd ed., Pierce Chem. Co., Rockford, Ill. (1984). Proteins of greater length may be synthesized by condensation of the amino and carboxy termini of shorter fragments. Methods of

03589530, 060700

forming peptide bonds by activation of a carboxy terminal end (e.g., by the use of the coupling reagent N,N'-dicyclohexylcarbodiimide)) is known to those of skill.

Purification of Proteins

The proteins of the present invention may be purified by standard techniques well known to those of skill in the art. Recombinantly produced proteins of the present invention can be directly expressed or expressed as a fusion protein. The recombinant protein is purified by a combination of cell lysis (e.g., sonication, French press) and affinity chromatography. For fusion products, subsequent digestion of the fusion protein with an appropriate proteolytic enzyme releases the desired recombinant protein.

The proteins of this invention, recombinant or synthetic, may be purified to substantial purity by standard techniques well known in the art, including detergent solubilization, selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes, *Protein Purification: Principles and Practice*, Springer-Verlag: New York (1982); Deutscher, *Guide to Protein Purification*, Academic Press (1990). For example, antibodies may be raised to the proteins as described herein. Purification from *E. coli* can be achieved following procedures described in U.S. Patent No. 4,511,503. The protein may then be isolated from cells expressing the protein and further purified by standard protein chemistry techniques as described herein. Detection of the expressed protein is achieved by methods known in the art and include, for example, radioimmunoassays, Western blotting techniques or immunoprecipitation.

Transgenic Plant Regeneration

Plants cells transformed with a plant expression vector can be regenerated, e.g., from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration from cultured protoplasts is described in Evans *et al.*, *Protoplasts Isolation and Culture*, *Handbook of Plant Cell Culture*, Macmillan Publishing Company, New York, pp. 124-176 (1983); and Binding, *Regeneration of Plants, Plant Protoplasts*, CRC Press, Boca Raton, pp. 21-73 (1985).

002090*01568560

The regeneration of plants containing the foreign gene introduced by *Agrobacterium* from leaf explants can be achieved as described by Horsch *et al.*, *Science*, 227:1229-1231 (1985). In this procedure, transformants are grown in the presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species being transformed as described by Fraley *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)*, 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Transgenic plants of the present invention may be fertile or sterile.

Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee *et al.*, *Ann. Rev. of Plant Phys.* 38: 467-486 (1987). The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, *Methods for Plant Molecular Biology*, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, Calif. (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots, rooting the transformant shoots and growth of the plantlets in soil. For maize cell culture and regeneration see generally, *The Maize Handbook*, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, 3rd edition, Sprague and Dudley Eds., American Society of Agronomy, Madison, Wisconsin (1988). One of skill will recognize that after the recombinant expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

In vegetatively propagated crops, mature transgenic plants can be propagated by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. Selection of desirable transgenics is made and new varieties are obtained and propagated vegetatively for commercial use. In seed propagated crops, mature transgenic plants can be self crossed to produce a homozygous inbred plant. The inbred plant produces seed containing the newly introduced heterologous nucleic acid. These seeds can be grown to produce plants that would produce the selected phenotype.

Parts obtained from the regenerated plant, such as flowers, seeds, leaves, branches, fruit, and the like are included in the invention, provided that these parts comprise cells comprising the isolated nucleic acid of the present invention. Progeny and

09589510-060700

variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced nucleic acid sequences.

Transgenic plants expressing the selectable marker can be screened for transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expression-positive plants. Standard techniques for RNA analysis can be employed and include PCR amplification assays using oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition, *in situ* hybridization and immunocytochemistry according to standard protocols can be done using heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Generally, a number of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.

A preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid; i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered expression of a polynucleotide of the present invention relative to a control plant (i.e., native, non-transgenic). Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.

Modulating Polypeptide Levels and/or Composition

The present invention further provides a method for modulating (i.e., increasing or decreasing) the concentration or ratio of the polypeptides of the present invention in a plant or part thereof. Modulation can be effected by increasing or decreasing the concentration and/or the ratio of the polypeptides of the present invention in a plant. The method comprises introducing into a plant cell with a recombinant expression

cassette comprising a polynucleotide of the present invention as described above to obtain a transformed plant cell, culturing the transformed plant cell under plant cell growing conditions, and inducing or repressing expression of a polynucleotide of the present invention in the plant for a time sufficient to modulate concentration and/or the ratios of the polypeptides in the plant or plant part.

In some embodiments, the concentration and/or ratios of polypeptides of the present invention in a plant may be modulated by altering, *in vivo* or *in vitro*, the promoter of a gene to up- or down-regulate gene expression. In some embodiments, the coding regions of native genes of the present invention can be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, e.g., Kmiec, U.S. Patent 5,565,350; Zarling *et al.*, PCT/US93/03868. And in some embodiments, an isolated nucleic acid (e.g., a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a polynucleotide of the present invention is selected for by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate the concentration and/or ratios of polypeptides of the present invention in the plant. Plant forming conditions are well known in the art and discussed briefly, *supra*.

In general, concentration or the ratios of the polypeptides is increased or decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by employing the appropriate promoter operably linked to a polynucleotide of the present invention in, for example, sense or antisense orientation as discussed in greater detail, *supra*. Induction of expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds which activate expression from these promoters are well known in the art. In preferred embodiments, the polypeptides of the present invention are modulated in monocots, particularly maize.

Molecular Markers

The present invention provides a method of genotyping a plant comprising a polynucleotide of the present invention. Optionally, the plant is a monocot, such as maize or sorghum. Genotyping provides a means of distinguishing homologs of a chromosome pair and can be used to differentiate segregants in a plant population. Molecular marker methods can be used for phylogenetic studies, characterizing genetic relationships among crop varieties, identifying crosses or somatic hybrids, localizing chromosomal segments affecting monogenic traits, map based cloning, and the study of quantitative inheritance. See, e.g., *Plant Molecular Biology: A Laboratory Manual*, Chapter 7, Clark, Ed., Springer-Verlag, Berlin (1997). For molecular marker methods, see generally, *The DNA Revolution* by Andrew H. Paterson 1996 (Chapter 2) in: *Genome Mapping in Plants* (ed. Andrew H. Paterson) by Academic Press/R. G. Landis Company, Austin, Texas, pp.7-21.

The particular method of genotyping in the present invention may employ any number of molecular marker analytic techniques such as, but not limited to, restriction fragment length polymorphisms (RFLPs). RFLPs are the product of allelic differences between DNA restriction fragments resulting from nucleotide sequence variability. As is well known to those of skill in the art, RFLPs are typically detected by extraction of genomic DNA and digestion with a restriction enzyme. Generally, the resulting fragments are separated according to size and hybridized with a probe; single copy probes are preferred. Restriction fragments from homologous chromosomes are revealed. Differences in fragment size among alleles represent an RFLP. Thus, the present invention further provides a means to follow segregation of a gene or nucleic acid of the present invention as well as chromosomal sequences genetically linked to these genes or nucleic acids using such techniques as RFLP analysis. Linked chromosomal sequences are within 50 centiMorgans (cM), often within 40 or 30 cM, preferably within 20 or 10 cM, more preferably within 5, 3, 2, or 1 cM of a gene of the present invention.

In the present invention, the nucleic acid probes employed for molecular marker mapping of plant nuclear genomes selectively hybridize, under selective hybridization conditions, to a gene encoding a polynucleotide of the present invention. In preferred embodiments, the probes are selected from polynucleotides of the present invention.

09589510.060700

Typically, these probes are cDNA probes or restriction-enzyme treated (e.g., *Pst* I) genomic clones. The length of the probes is discussed in greater detail, *supra*, but are typically at least 15 bases in length, more preferably at least 20, 25, 30, 35, 40, or 50 bases in length. Generally, however, the probes are less than about 1 kilobase in length.

5 Preferably, the probes are single copy probes that hybridize to a unique locus in a haploid chromosome complement. Some exemplary restriction enzymes employed in RFLP mapping are *Eco*RI, *Eco*Rv, and *Sst*I. As used herein the term "restriction enzyme" includes reference to a composition that recognizes and, alone or in conjunction with another composition, cleaves at a specific nucleotide sequence.

10 The method of detecting an RFLP comprises the steps of (a) digesting genomic DNA of a plant with a restriction enzyme; (b) hybridizing a nucleic acid probe, under selective hybridization conditions, to a sequence of a polynucleotide of the present of said genomic DNA; (c) detecting therefrom a RFLP. Other methods of differentiating polymorphic (allelic) variants of polynucleotides of the present invention can be had by
15 utilizing molecular marker techniques well known to those of skill in the art including such techniques as: 1) single stranded conformation analysis (SSCA); 2) denaturing gradient gel electrophoresis (DGGE); 3) RNase protection assays; 4) allele-specific oligonucleotides (ASOs); 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein; and 6) allele-specific PCR. Other approaches based on
20 the detection of mismatches between the two complementary DNA strands include clamped denaturing gel electrophoresis (CDGE); heteroduplex analysis (HA); and chemical mismatch cleavage (CMC). Thus, the present invention further provides a method of genotyping comprising the steps of contacting, under stringent hybridization conditions, a sample suspected of comprising a polynucleotide of the present invention
25 with a nucleic acid probe. Generally, the sample is a plant sample; preferably, a sample suspected of comprising a maize polynucleotide of the present invention (e.g., gene, mRNA). The nucleic acid probe selectively hybridizes, under stringent conditions, to a subsequence of a polynucleotide of the present invention comprising a polymorphic marker. Selective hybridization of the nucleic acid probe to the polymorphic marker
30 nucleic acid sequence yields a hybridization complex. Detection of the hybridization complex indicates the presence of that polymorphic marker in the sample. In preferred embodiments, the nucleic acid probe comprises a polynucleotide of the present invention.

00000000-00000000

UTRs and Codon Preference

In general, translational efficiency has been found to be regulated by specific sequence elements in the 5' non-coding or untranslated region (5' UTR) of the RNA. Positive sequence motifs include translational initiation consensus sequences (Kozak, *Nucleic Acids Res.* 15:8125 (1987)) and the 7-methylguanosine cap structure (Drummond *et al.*, *Nucleic Acids Res.* 13:7375 (1985)). Negative elements include stable intramolecular 5' UTR stem-loop structures (Muesing *et al.*, *Cell* 48:691 (1987)) and AUG sequences or short open reading frames preceded by an appropriate AUG in the 5' UTR (Kozak, *supra*, Rao *et al.*, *Mol. and Cell. Biol.* 8:284 (1988)). Accordingly, the present invention provides 5' and/or 3' UTR regions for modulation of translation of heterologous coding sequences.

Further, the polypeptide-encoding segments of the polynucleotides of the present invention can be modified to alter codon usage. Altered codon usage can be employed to alter translational efficiency and/or to optimize the coding sequence for expression in a desired host such as to optimize the codon usage in a heterologous sequence for expression in maize. Codon usage in the coding regions of the polynucleotides of the present invention can be analyzed statistically using commercially available software packages such as "Codon Preference" available from the University of Wisconsin Genetics Computer Group (see Devereaux *et al.*, *Nucleic Acids Res.* 12: 387-395 (1984)) or MacVector 4.1 (Eastman Kodak Co., New Haven, Conn.). Thus, the present invention provides a codon usage frequency characteristic of the coding region of at least one of the polynucleotides of the present invention. The number of polynucleotides that can be used to determine a codon usage frequency can be any integer from 1 to the number of polynucleotides of the present invention as provided herein. Optionally, the polynucleotides will be full-length sequences. An exemplary number of sequences for statistical analysis can be at least 1, 5, 10, 20, 50, or 100.

Sequence Shuffling

The present invention provides methods for sequence shuffling using polynucleotides of the present invention, and compositions resulting therefrom. Sequence shuffling is described in PCT publication No. WO 97/20078. See also, Zhang, J.-H., *et al. Proc. Natl. Acad. Sci. USA* 94:4504-4509 (1997). Generally, sequence shuffling provides a means for generating libraries of polynucleotides having a desired

000000-01568555

characteristic which can be selected or screened for. Libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides which comprise sequence regions which have substantial sequence identity and can be homologously recombined in vitro or in vivo. The population of sequence-recombined polynucleotides comprises a subpopulation of polynucleotides which possess desired or advantageous characteristics and which can be selected by a suitable selection or screening method. The characteristics can be any property or attribute capable of being selected for or detected in a screening system, and may include properties of: an encoded protein, a transcriptional element, a sequence controlling transcription, RNA processing, RNA stability, chromatin conformation, translation, or other expression property of a gene or transgene, a replicative element, a protein-binding element, or the like, such as any feature which confers a selectable or detectable property. In some embodiments, the selected characteristic will be a decreased K_m and/or increased K_{cat} over the wild-type protein as provided herein. In other embodiments, a protein or polynucleotide generated from sequence shuffling will have a ligand binding affinity greater than the non-shuffled wild-type polynucleotide. The increase in such properties can be at least 110%, 120%, 130%, 140% or at least 150% of the wild-type value.

Generic and Consensus Sequences

Polynucleotides and polypeptides of the present invention further include those having: (a) a generic sequence of at least two homologous polynucleotides or polypeptides, respectively, of the present invention; and, (b) a consensus sequence of at least three homologous polynucleotides or polypeptides, respectively, of the present invention. The generic sequence of the present invention comprises each species of polypeptide or polynucleotide embraced by the generic polypeptide or polynucleotide, sequence, respectively. The individual species encompassed by a polynucleotide having an amino acid or nucleic acid consensus sequence can be used to generate antibodies or produce nucleic acid probes or primers to screen for homologs in other species, genera, families, orders, classes, phylums, or kingdoms. For example, a polynucleotide having a consensus sequences from a gene family of *Zea mays* can be used to generate antibody or nucleic acid probes or primers to other *Gramineae* species such as wheat, rice, or sorghum. Alternatively, a polynucleotide having a consensus sequence generated from orthologous genes can be used to identify or isolate orthologs of other taxa. Typically, a

polynucleotide having a consensus sequence will be at least 9, 10, 15, 20, 25, 30, or 40 amino acids in length, or 20, 30, 40, 50, 100, or 150 nucleotides in length. As those of skill in the art are aware, a conservative amino acid substitution can be used for amino acids which differ amongst aligned sequence but are from the same conservative substitution group as discussed above. Optionally, no more than 1 or 2 conservative amino acids are substituted for each 10 amino acid length of consensus sequence.

Similar sequences used for generation of a consensus or generic sequence include any number and combination of allelic variants of the same gene, orthologous, or paralogous sequences as provided herein. Optionally, similar sequences used in generating a consensus or generic sequence are identified using the BLAST algorithm's smallest sum probability (P(N)). Various suppliers of sequence-analysis software are listed in chapter 7 of *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (Supplement 30). A polynucleotide sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, or 0.001, and most preferably less than about 0.0001, or 0.00001. Similar polynucleotides can be aligned and a consensus or generic sequence generated using multiple sequence alignment software available from a number of commercial suppliers such as the Genetics Computer Group's (Madison, WI) PILEUP software, Vector NTI's (North Bethesda, MD) ALIGNX, or Genecode's (Ann Arbor, MI) SEQUENCHER. Conveniently, default parameters of such software can be used to generate consensus or generic sequences.

Assays for Compounds that Modulate Enzymatic Activity or Expression

The present invention also provides means for identifying compounds that bind to (e.g., substrates), and/or increase or decrease (i.e., modulate) the enzymatic activity of, catalytically active polypeptides of the present invention. The method comprises contacting a polypeptide of the present invention with a compound whose ability to bind to or modulate enzyme activity is to be determined. The polypeptide employed will have at least 20%, preferably at least 30% or 40%, more preferably at least 50% or 60%, and most preferably at least 70% or 80% of the specific activity of the native, full-length polypeptide of the present invention (e.g., enzyme). Generally, the polypeptide will be

09589510-060700

present in a range sufficient to determine the effect of the compound, typically about 1 nM to 10 μ M. Likewise, the compound will be present in a concentration of from about 1 nM to 10 μ M. Those of skill will understand that such factors as enzyme concentration, ligand concentrations (i.e., substrates, products, inhibitors, activators), pH, ionic strength, and temperature will be controlled so as to obtain useful kinetic data and determine the presence or absence of a compound that binds or modulates polypeptide activity. Methods of measuring enzyme kinetics is well known in the art. See, e.g., Segel, *Biochemical Calculations*, 2nd ed., John Wiley and Sons, New York (1976).

Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Example 1

This example describes the construction of the cDNA libraries.

Total RNA Isolation

Total RNA was isolated from corn tissues with TRIZOL Reagent (Life Technology Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanate/acid-phenol procedure described by Chomczynski and Sacchi (Chomczynski, P., and Sacchi, N. *Anal. Biochem.* 162, 156 (1987)). In brief, plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIZOL Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform followed by centrifugation was conducted for separation of an aqueous phase and an organic phase. The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.

Poly(A)+ RNA Isolation

The selection of poly(A)+ RNA from total RNA was performed using POLYATTRACT system (Promega Corporation. Madison, WI). In brief, biotinylated oligo(dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic

separation stand. The mRNA was washed at high stringency conditions and eluted by RNase-free deionized water.

cDNA Library Construction

cDNA synthesis was performed and unidirectional cDNA libraries were constructed using the SUPERScript Plasmid System (Life Technology Inc. Gaithersburg, MD). The first strand of cDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by SUPERScript Reverse Transcriptase II at 45°C. The second strand of cDNA was labeled with alpha-³²P-dCTP and a portion of the reaction was analyzed by agarose gel electrophoresis to determine cDNA sizes. cDNA molecules smaller than 500 base pairs and unligated adapters were removed by SEPHACRYL-S400 chromatography. The selected cDNA molecules were ligated into pSPORT1 vector in between of *Nor* I and *Sal* I sites.

Example 2

This example describes cDNA sequencing and library subtraction.

Sequencing Template Preparation

Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid isolation. All the cDNA clones were sequenced using M13 reverse primers.

Q-bot Subtraction Procedure

cDNA libraries subjected to the subtraction procedure were plated out on 22 x 22 cm² agar plate at density of about 3,000 colonies per plate. The plates were incubated in a 37°C incubator for 12-24 hours. Colonies were picked into 384-well plates by a robot colony picker, Q-bot (GENETIX Limited). These plates were incubated overnight at 37°C.

Once sufficient colonies were picked, they were pinned onto 22 x 22 cm² nylon membranes using Q-bot. Each membrane contained 9,216 colonies or 36,864 colonies. These membranes were placed onto agar plate with appropriate antibiotic. The plates were incubated at 37°C for overnight.

09589510-060700

After colonies were recovered on the second day, these filters were placed on filter paper prewetted with denaturing solution for four minutes, then were incubated on top of a boiling water bath for additional four minutes. The filters were then placed on filter paper prewetted with neutralizing solution for four minutes. After excess solution was removed by placing the filters on dry filter papers for one minute, the colony side of the filters were placed into Proteinase K solution, incubated at 37°C for 40-50 minutes. The filters were placed on dry filter papers to dry overnight. DNA was then cross-linked to nylon membrane by UV light treatment.

Colony hybridization was conducted as described by Sambrook, J., Fritsch, E.F. and Maniatis, T., (in *Molecular Cloning: A laboratory Manual*, 2nd Edition). The following probes were used in colony hybridization:

1. First strand cDNA from the same tissue as the library was made from to remove the most redundant clones.
2. 48-192 most redundant cDNA clones from the same library based on previous sequencing data.
3. 192 most redundant cDNA clones in the entire corn sequence database.
4. A Sal-A20 oligo nucleotide: TCG ACC CAC GCG TCC GAA AAA AAA AAA AAA AAA AAA, listed in SEQ ID NO: 11, removes clones containing a poly A tail but no cDNA.
5. cDNA clones derived from rRNA.

The image of the autoradiography was scanned into computer and the signal intensity and cold colony addresses of each colony was analyzed. Re-arraying of cold-colonies from 384 well plates to 96 well plates was conducted using Q-bot.

Example 3

This example describes identification of the gene from a computer homology search.

Gene identities were determined by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1990) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches under default parameters for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure

Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm. The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish, W. and States, D. J. *Nature Genetics* 3:266-272 (1993)) provided by the NCBI. In some cases, the sequencing data from two or more clones containing overlapping segments of DNA were used to construct contiguous DNA sequences.

Example 4

This example shows the conservation of structural motifs in Maize RuvB orthologues. The deduced amino acid sequences of the Maize RuvB orthologues are indicated by their SEQ ID number. The amino acids constituting the ATP binding motifs, also known as Walker Box A and Walker Box B, are indicated (Walker Box A is highlighted while Walker Box B is shown in **bold**). Regions of high homology to bacterial RuvB are underlined and the putative heptad repeat region is *italicized*.

```

1                               50
Seq_Id_No6 MRIEEVQSTS KKQRIATHTH IKGLGLD.AN GMSMPLAAGF VGQAAAREAA
Seq_Id_No8 MRIEEVQSTS KKQRIATHTH IKGLGLDQAN GMSMPLAAGF VGQAAAREAA
Seq_Id_No2 MRIEEVQSTS KKQRIATHTH IKGLGLD.AN GMAIALAAGF VGQSAAREAA
Seq_Id_No4 MRIEEVQSTS KKQRIATHTH IKGLGLD.AN GMAIALAAGF VGQAAAREAA
Seq_Id_No10 MRIEEVQSTS KKQRIATHTH IKGLGLD.AN GMAIALAAGF VG.....

51                               100
Seq_Id_No6 GLAVDMIRQK KMAGRALLA GPPATGKTAL ALGIAQELGS KVPFPCMVGS
Seq_Id_No8 GLAVDMIRQK KMAGRALLA GPPATGKTAL ALGIAQELGS KVPFPCMVGS
Seq_Id_No2 GLAVDMIRQK KMAGRAVLV GPPATGKTAL ALGIAQELGS KVPFPCMVGS
Seq_Id_No4 GLAVDMIRQK KMAGRAVLLA GPPATGKTAL ALGIAQELGS KVPFPCMVGS
Seq_Id_No10 .....OK KMAGRAVLLA GPPATGKTAL A.GIAQELGS KVPFPCMVGS

101                               150
Seq_Id_No6 EVYSSEVKKT EVLMENFRA IGLRIKENKE VYEGEVIELS PEEABSTTGG
Seq_Id_No8 EVYSSEVKKT EVLMENFRA IGLRIKENKE VYEGEVIELS PEEABSTTGG
Seq_Id_No2 EVYSSEVKKT EVLMENFRA IGLRIKENKE VYEGEVIELS PEEABSTTGG
Seq_Id_No4 EVYSSEVKKT EVLMENFRA IGLRIKENKE VYEGEVIELS PEEABSTTGG
Seq_Id_No10 EVYSSEVKKT EVLMENFRA IGLRIKENKE VYEGEVIELS PEEABSTTGG

151                               200
Seq_Id_No6 YAKSISHVII GLKTVKGTKQ LKLDPSIYDA LIKEKVAVDG VIYIEANSNGA
Seq_Id_No8 YAKSISHVII GLKTVKGTKQ LKLDPSIYDA LIKEKVAVDG VIYIEANSNGA
Seq_Id_No2 YAKSISHVII SLKTVKGTKQ LKLDSSIYDA LIKEKVAVDG VIYIEANSNGA
Seq_Id_No4 YAKSISHVII SLKTVKGTKQ LKLDSSIYDA LIKEKVAVDG VIYIEANSNGA
Seq_Id_No10 YAKSISHVII SLKTVKGTKQ LKLDSSIYDA LIKEKVAVDG VIYIEANSNGA

```

		201	250
	Seq_Id_No6	VKRVRGCDSF ATEYDLEAEE YVPIPKGEVH KKKKIVQDVT LHLDAANAQ	
	Seq_Id_No8	VKRVRGCDSF ATEYDLEAEE YVPIPKGEVH KKKKIVQDVT LHLDAANAQ	
5	Seq_Id_No2	VKRVRGCDSF ATEYDLEAEE YVPIPKGEVH KKKKIVQDVT LHLDAANAQ	
	Seq_Id_No4	VKRVRGCDSF ATEYDLEAEE YVPIPKGEVH KKKKIVQDVT LHLDAANAQ	
	Seq_Id_No10	VKRVRGCDSF ATEYDLEAEE YVPIPKGEVH KKKKIVQDVT LHLDAANAQ	
		251	300
10	Seq_Id_No6	PQGGQDILSL MGQMMKPRKT EITEKLQEI NKVVNRYIDE GIAELVPGVL	
	Seq_Id_No8	PQGGQDILSL MGQMMKPRKT EITEKLQEI NKVVNRYIDE GIAELVPGVL	
	Seq_Id_No2	PQGGQDILSL MGQMMKPRKT EITEKLQEI NKVVNRYIDE GIAELVPGVL	
	Seq_Id_No4	PQGGQDILSL MGQMMKPRKT EITEKLQEI NKVVNRYIDE GIAELVPGVL	
	Seq_Id_No10	PQGGQDILSL MGQMMKPRKT EITEKLQEI NKVVNRYIDE GIAELVPGVL	
15			
		301	350
	Seq_Id_No6	<u>FIDEVHMLDI</u> <u>ECFSYLNRL</u> <u>ESPLSPIVL</u> <u>ATNRGICNVR</u> <u>GTDMTSPHGI</u>	
	Seq_Id_No8	<u>FIDEVHMLDI</u> <u>ECFSYLNRL</u> <u>ESPLSPIVL</u> <u>ATNRGICNVR</u> <u>GTDMTSPHGI</u>	
20	Seq_Id_No2	<u>FIDEVHMLDI</u> <u>ECFSYLNRL</u> <u>ESPLSPIVL</u> <u>ATNRGICNVR</u> <u>GTDMTSPHGI</u>	
	Seq_Id_No4	<u>FIDEVHMLDI</u> <u>ECFSYLNRL</u> <u>ESPLSPIVL</u> <u>ATNRGICNVR</u> <u>GTDMTSPHGI</u>	
	Seq_Id_No10	<u>FIDEVHMLDI</u> <u>ECFSYLNRL</u> <u>ESPLSPIVL</u> <u>ATNRGICNVR</u> <u>GTDMTSPHGI</u>	
		351	400
	Seq_Id_No6	<u>PVDLLDLRLVI</u> <u>IRTETYGPT</u> <u>EQILAIRAQ</u> <u>VEEDIMDEES</u> <u>LAYLGEIGQQ</u>	
25	Seq_Id_No8	<u>PVDLLDLRLVI</u> <u>IRTETYGPT</u> <u>EQILAIRAQ</u> <u>VEEDIMDEES</u> <u>LAYLGEIGQQ</u>	
	Seq_Id_No2	<u>PVDLLDLRLVI</u> <u>IRTETYGPT</u> <u>EQILAIRAQ</u> <u>VEEDIMDEES</u> <u>LAYLGEIGQQ</u>	
	Seq_Id_No4	<u>PVDLLDLRLVI</u> <u>IRTETYGPT</u> <u>EQILAIRAQ</u> <u>VEEDIMDEES</u> <u>LAYLGEIGQQ</u>	
	Seq_Id_No10	<u>PVDLLDLRLVI</u> <u>IRTETYGPT</u> <u>EQILAIRAQ</u> <u>VEEDIMDEES</u> <u>LAYLGEIGQQ</u>	
30			
		401	450
	Seq_Id_No6	<u>TSLRHAIQLL</u> <u>SPASVVAKTN</u> <u>GREKCKADL</u> <u>EEVSGLYLDA</u> <u>KSSARLLQEQ</u>	
	Seq_Id_No8	<u>TSLRHAIQLL</u> <u>SPASVVAKTN</u> <u>GREKCKADL</u> <u>EEVSGLYLDA</u> <u>KSSARLLQEQ</u>	
	Seq_Id_No2	<u>TSLRHAIQLI</u> <u>SPASVVSKTN</u> <u>GREKICKADL</u> <u>EEVSGLYLDA</u> <u>KSSARLLQEQ</u>	
	Seq_Id_No4	<u>TSLRHAIQLI</u> <u>SPASVVSKTN</u> <u>GREKICKADL</u> <u>EEVSGLYLDA</u> <u>KSSARLLQEQ</u>	
35	Seq_Id_No10	<u>TSLRHAIQLI</u> <u>SPASVVSKTN</u> <u>GREKICKADL</u> <u>EEVSGLYLDA</u> <u>KSSARLLQEQ</u>	
		451	
	Seq_Id_No6	QERYIT*	
	Seq_Id_No8	QERYIT*	
40	Seq_Id_No2	QERYIT*	
	Seq_Id_No4	QERYIT*	
	Seq_Id_No10	QERYIT*	

45 The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, patent applications, and computer programs cited herein are hereby incorporated by reference.

002090-0156856

1. An isolated nucleic acid comprising a member selected from the group consisting of:

- (a) a polynucleotide having at least 85% sequence identity to a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3, and 9, wherein the % sequence identity is based on the entire coding regions and is calculated by the GAP algorithm under default parameters;
 - (b) a polynucleotide encoding a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, and 10;
 - (c) a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3, and 9; and
 - (d) a polynucleotide which is complementary to a polynucleotide of (a), (b), or (c).
2. An isolated polynucleotide comprising a member selected from the group consisting of:
 - (a) a polynucleotide encoding a polypeptide selected from the group consisting of SEQ ID NOS: 6 and 8;
 - (b) a polynucleotide selected from the group consisting of SEQ ID NOS: 5 and 7; and
 - (c) a polynucleotide which is complementary to a polynucleotide of (a) or (b).
3. A recombinant expression cassette comprising a polynucleotide operably linked, in sense or anti-sense orientation, to a promoter, wherein said polynucleotide is selected from the group consisting of a member of claim 1 and a member of claim 2.
4. A host cell comprising the recombinant expression cassette of claim 3.
5. A transgenic plant comprising a recombinant expression cassette of claim 3.
6. The transgenic plant of claim 5, wherein said plant is a monocot.

7. The transgenic plant of claim 5, wherein said plant is a dicot.
8. The transgenic plant of claim 5, wherein said plant is selected from the group consisting of: corn, soybean, sunflower, sorghum, canola, wheat, alfalfa, cotton, rice, barley, and millet.
9. A transgenic seed from the transgenic plant of claim 5.
10. A method of modulating the level of RuvB in a plant cell, comprising:
 - (a) introducing into a plant cell a recombinant expression cassette comprising a RuvB polynucleotide operably linked to a promoter, wherein said RuvB polynucleotide is selected from the group consisting of a member of claim 1 and a member of claim 2;
 - (b) culturing the plant cell under plant cell growing conditions; and
 - (c) inducing expression of said RuvB polynucleotide for a time sufficient to modulate the level of RuvB in said plant cell.
11. A method of modulating the level of RuvB in a plant, comprising:
 - (a) introducing into a plant cell a recombinant expression cassette comprising a RuvB polynucleotide operably linked to a promoter, wherein said RuvB polynucleotide is selected from the group consisting of a member of claim 1 and a member of claim 2;
 - (b) culturing the plant cell under plant cell growing conditions;
 - (c) regenerating a whole plant which possesses the transformed genotype; and
 - (d) inducing expression of said RuvB polynucleotide for a time sufficient to modulate the level of RuvB in said plant.
12. The method of claim 11, wherein said plant is maize.
13. An isolated protein comprising a member selected from the group consisting of:
 - (a) a polypeptide of at least 20 contiguous amino acids from a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, and 10;

09589510.060700

- (b) a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, and 10;
- (c) a polypeptide having at least 80% sequence identity to, and having at least one linear epitope in common with, a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, and 10; and
- (d) at least one polypeptide encoded by a polynucleotide selected from the group consisting of a member of claim 1 and a member of claim 2.

09589510-060700

ABSTRACT OF THE DISCLOSURE

The invention provides isolated maize RuvB nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering maize RuvB levels in plants. The invention further provides recombinant expression
5 cassettes, host cells, transgenic plants, and antibody compositions.

09589510.060700

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Maize Orthologues of Bacterial RuvB: cDNAs and Uses Thereof

the specification of which (check one)

☒

is attached hereto

was filed on _____ as Application Serial No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign or provisional application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

NUMBER	COUNTRY	MONTH/DAY/YEAR FILED	PRIORITY CLAIMED

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of

09589510-060700

Federal Regulations §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS: PATENTED, PENDING, ABANDONED
60/144,112	7/16/99	Pending

I hereby appoint as my attorneys and/agents, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Debra L. Blair	Registration No. 39,112
Donna Bobrowicz	Registration No. 32,196
Jean M. Bromert	Registration No. 42,362
Catherine D. Brooke	Registration No. 44,041
Karen Moon Bruce	Registration No. 42,366
Steven J. Callistein	Registration No. 43,525
Amy L. Cigan	Registration No. 45,494
Herbert H. Jervis	Registration No. 31,171
Marianne H. Michel	Registration No. 35,286
David B. Ran	Registration No. 38,589
Patricia A. Sweeney	Registration No. 32,733
Karen K. Varley	Registration No. 45,751
Michael E. Yates	Registration No. 36,063

Send Correspondence to:

Amy L. Cigan
Patent Counsel
7100 N.W. 62nd Avenue
P.O. Box 1000
Johnston, Iowa 50131-1000

Direct telephone calls to:

Amy L. Cigan
(515) 248-4896

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor	Signature of First or Sole Inventor	Date
Pramod B. Mahajan	<i>PB Mahajan</i>	6-6-2000
Residence Address	Country or Citizenship	
8029 Brookview Drive, Urbandale, Iowa	United States of America	
Post Office Address		

Docket No. 1121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pramod B. Mahajan

Date: June 7, 2000

Serial No.:

Group Art Unit:

Filed June 7, 2000

Examiner:

For: "Maize Orthologues of Bacterial RuvB: cDNAs and Uses Thereof"

Assistant Commissioner for Patents

Box Sequence


Washington, D.C. 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§1.821 THROUGH 1.825

- ☒ I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ☐ I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,



Amy L. Cigan

Agent for Applicant(s)

Registration No. 45,494

PIONEER HI-BRED INTERNATIONAL, INC.

Corporate Intellectual Property

7100 N.W. 62nd Avenue

P.O. Box 1000

Johnston, Iowa 50131-1000

Phone: (515) 248-4896

Facsimile: (515) 334-6883

09589510-060700

SEQUENCE LISTING

<110> Mahajan, Pramod B.

<120> Maize Orthologues of Bacterial RuvB:
cDNAs and Uses Thereof

<130> 1121

<150> US 60/144,112

<151> 1999-07-16

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1845

<212> DNA

<213> Zea mays

<220>

<221> CDS

<222> (85)...(1449)

<400> 1

gacccacgcg	tcgcgccatcc	cccgccccca	aattttggca	gctccacaga	aacagagagc	60
gcataaccgg	cgttggttggc	ggcg	atg agg atc gag gag	gtg cag	tcg acc	111
			Met Arg Ile Glu Glu Val Gln Ser Thr			
		1		5		
tcg aag aag	cag cgc atc gcc acc	cac acc	cac atc aag gga	ctc gcc		159
Ser Lys Lys	Gln Arg Ile Ala Thr	His Thr	His Ile Lys Gly Leu Gly			
10	15		20	25		
ctc gac gcc	aat ggg atg gcg att	gcg ttg gcg gcg ggg	ttc gtg gcc			207
Leu Asp Ala	Asn Gly Met Ala Ile Ala	Leu Ala Ala Gly Phe Val Gly				
	30	35	40			
cag tcg gcg gcg cgc	gag gcg gcc ggg	ctg gcg gtc gac atg att	cgc			255
Gln Ser Ala Ala Arg	Glu Ala Ala Gly Leu Ala Val	Asp Met Ile Arg				
	45	50	55			
cag aaa aag atg gcc	ggc cgc gcg gtg ctc ctt	gtg ggt ccg ccc gcc				303
Gln Lys Lys Met Ala	Gly Arg Ala Val Leu Leu Val	Gly Pro Pro Ala				
	60	65	70			
acg gcc aag acg gcg	cta gcg ctc gcc ata gcc	cag gag ctc gcc agc				351
Thr Gly Lys Thr Ala	Leu Ala Leu Gly Ile Ala Glu Leu Gly Ser					
	75	80	85			
aag gtc cct ttc tgc	cct atg gta gga tca gaa	gtg tac tcc tcg gag				399
Lys Val Pro Phe Cys	Pro Met Val Gly Ser Glu Val Tyr Ser	Ser Ser Glu				
	90	95	100	105		
gtc aag aaa act gag	gtg ctg atg gaa aat ttc	cgt aga gct ata ggt				447
Val Lys Lys Thr Glu	Val Leu Met Glu Asn Phe Arg Arg Ala Ile Gly					
	110	115	120			

002090.0150856

ttg cgt ata aag gaa aac aaa gag gtt tat gaa gga gag gtt act gaa Leu Arg Ile Lys Glu Asn Lys Glu Val Tyr Glu Gly Glu Val Thr Glu	495
125 130 135	
ctt tcc cca gaa gag gct gag agt aca act ggt gga tat gca aaa agc Leu Ser Pro Glu Glu Ala Glu Ser Thr Thr Gly Tyr Ala Lys Ser	543
140 145 150	
att agc cat gta atc atc agc tta aag act gtt aaa ggg act aag caa Ile Ser His Val Ile Ile Ser Leu Lys Thr Val Lys Gly Thr Lys Gln	591
155 160 165	
ctg aag tta gat tct tca att tat gat gct ctg atc aag gaa aag gtg Leu Lys Leu Asp Ser Ser Ile Tyr Asp Ala Leu Ile Lys Glu Lys Val	639
170 175 180 185	
gca gtg ggt gat gtt ata tac att gaa gca aat agt gga gca gtg aaa Ala Val Gly Asp Val Ile Tyr Ile Glu Ala Asn Ser Gly Ala Val Lys	687
190 195 200	
aga gtt ggt aga tgt gat tct ttt gct aca gaa tac gat ctt gaa gct Arg Val Gly Arg Cys Asp Ser Phe Ala Thr Glu Tyr Asp Leu Glu Ala	735
205 210 215	
gaa gaa tat gtt cct atc ccc aaa ggt gaa gtc cat aag aaa aaa gaa Glu Glu Tyr Val Pro Ile Pro Lys Gly Glu Val His Lys Lys Lys Glu	783
220 225 230	
ata gtg cag gat gtc aca ctt cat gac ctt gat gca gca aat gct cag Ile Val Gln Asp Val Thr Leu His Asp Leu Asp Ala Ala Asn Ala Gln	831
235 240 245	
cca caa ggt ggc caa gat att ttg tcc ctt atg ggc cag atg atg aaa Pro Gln Gly Gly Gln Asp Ile Leu Ser Leu Met Gly Gln Met Met Lys	879
250 255 260 265	
cca cga aag act gaa atc acc gaa aaa cta cgc caa gaa att aat aag Pro Arg Lys Thr Glu Ile Thr Glu Lys Leu Arg Gln Glu Ile Asn Lys	927
270 275 280	
gtg gta aat aga tat atc gat gaa gga att gca gag ctt gta cct ggt Val Val Asn Arg Tyr Ile Asp Glu Gly Ile Ala Glu Leu Val Pro Gly	975
285 290 295	
gtt tta ttc att gac gag gtc cac atg ttg gat atc gaa tgt ttt tct Val Leu Phe Ile Asp Glu Val His Met Leu Asp Ile Glu Cys Phe Ser	1023
300 305 310	
tat ctt aac cgt gca ttg gag agc cca tta tca cca att gtg ata ctt Tyr Leu Asn Arg Ala Leu Glu Ser Pro Leu Ser Pro Ile Val Ile Leu	1071
315 320 325	
gct acg aat agg gga ata tgt aat gta aga gga act gat atg aca agt Ala Thr Asn Arg Gly Ile Cys Asn Val Arg Gly Thr Asp Met Thr Ser	1119
330 335 340 345	
cca cat ggt ata cca gtg gat ctt cta gat agg ttg gtg att att cgg Pro His Gly Ile Pro Val Asp Leu Leu Asp Arg Leu Val Ile Ile Arg	1167
350 355 360	

00589510.060700

aca gag aca tat ggc cct act gag atg ata cag ata ttg gct atc cga 1215
 Thr Glu Thr Tyr Gly Pro Thr Glu Met Ile Gln Ile Leu Ala Ile Arg
 365 370 375

gca caa gtg gag gac att gat atg gat gaa gaa agt ctt gct tat tta 1263
 Ala Gln Val Glu Asp Ile Asp Met Asp Glu Glu Ser Leu Ala Tyr Leu
 380 385 390

ggc gag atc gga cag cag aca tct tta aga cat gct att caa ttg ata 1311
 Gly Glu Ile Gly Gln Gln Thr Ser Leu Arg His Ala Ile Gln Leu Ile
 395 400 405

tca cct gcc agc gtg gtc tca aag act aat gga aga gag aaa ata tgc 1359
 Ser Pro Ala Ser Val Val Ser Lys Thr Asn Gly Arg Glu Lys Ile Cys
 410 415 420 425

aag gct gat ctc gag gaa gtc agt ggg ctc tat ttg gat gcc aaa tcc 1407
 Lys Ala Asp Leu Glu Glu Val Ser Gly Leu Tyr Leu Asp Ala Lys Ser
 430 435 440

tcg gct cgg ctg ctc cag gag caa caa gaa aga tac atc acc 1449
 Ser Ala Arg Leu Leu Gln Glu Gln Gln Glu Arg Tyr Ile Thr
 445 450 455

tagatttga tcacctgtcg tggaagtctc gaagagaatg tagttgccag ctcgaaagtc 1509
 atctagtga atgtatctgct tcacaggtct tggagcgagc acatttcggg ggggacggct 1569
 tgaattttgc agtgcctgct tgtgttagtc tccagagaag acttggtacc ggcatattgc 1629
 ctgttcacgc actgttctgct gattagattg gtcaccgggt caggaattgc cgtgtgtggt 1689
 ttttatcttg ctcatcggtg tccggaatct gtgcctccac ggggtgtatt ggcccgaacc 1749
 ctatctttgt aaccatggat aatggatagc attctttacag aatgcaactt gcatggcttt 1809
 wttwaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1845

<210> 2
 <211> 455
 <212> PRT
 <213> Zea mays

<400> 2
 Met Arg Ile Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala
 1 5 10 15
 Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Ala Asn Gly Met Ala
 20 25 30
 Ile Ala Leu Ala Ala Gly Phe Val Gly Gln Ser Ala Ala Arg Glu Ala
 35 40 45
 Ala Gly Leu Ala Val Asp Met Ile Arg Gln Lys Lys Met Ala Gly Arg
 50 55 60
 Ala Val Leu Leu Val Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu Ala
 65 70 75 80
 Leu Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met
 85 90 95
 Val Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu
 100 105 110
 Met Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys
 115 120 125
 Glu Val Tyr Glu Gly Glu Val Thr Glu Leu Ser Pro Glu Glu Ala Glu
 130 135 140
 Ser Thr Thr Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Ser
 145 150 155 160
 Leu Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Ser Ser Ile
 165 170 175
 Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr
 180 185 190

00509510.060700

Ile Glu Ala Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser
 195 200 205
 Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu Tyr Val Pro Ile Pro
 210 215 220
 Lys Gly Glu Val His Lys Lys Glu Ile Val Gln Asp Val Thr Leu
 225 230 235 240
 His Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile
 245 250 255
 Leu Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr
 260 265 270
 Glu Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp
 275 280 285
 Glu Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val
 290 295 300
 His Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu
 305 310 315 320
 Ser Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys
 325 330 335
 Asn Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp
 340 345 350
 Leu Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr
 355 360 365
 Glu Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Asp Ile Asp
 370 375 380
 Met Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr
 385 390 395 400
 Ser Leu Arg His Ala Ile Gln Leu Ile Ser Pro Ala Ser Val Val Ser
 405 410 415
 Lys Thr Asn Gly Arg Glu Lys Ile Cys Lys Ala Asp Leu Glu Glu Val
 420 425 430
 Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Glu Gln Glu
 435 440 445
 Gln Gln Glu Arg Tyr Ile Thr
 450 455

<210> 3
 <211> 1912
 <212> DNA
 <213> Zea mays
 <220>
 <221> CDS
 <222> (94)...(1458)

<400> 3
 acccagcggt ccgcaaatatt gttgcgcgcg gagagccgga gaggaggcag ctccacagaa 60
 acagagagcgc cataaccggc ggcgttgccg cgc atg agg atc gag gag gtg cag 114
 Met Arg Ile Glu Glu Val Gln
 1 5
 tcg acc tcg aag aag cag cgc atc gcc acc cac acc cac atc aag gga 162
 Ser Thr Ser Lys Lys Gln Arg Ile Ala Thr His Thr His Ile Lys Gly
 10 15 20
 ctc ggc ctc gac gcc aat ggg atg cgc att cgc ttg cgc ggc ggg ttc 210
 Leu Gly Leu Asp Ala Asn Gly Met Ala Ile Ala Leu Ala Ala Gly Phe
 25 30 35
 gtg ggc cag cgc ggc cgc cgc gag cgc gcc ggg ctg cgc gtc gac atg 258
 Val Gly Gln Ala Ala Ala Arg Glu Ala Ala Gly Leu Ala Val Asp Met
 40 45 50 55

09589510.060700

att cgc cag aag aag atg gcc ggc cgc gcg gtg ctc ctt gcg ggt ccg Ile Arg Gln Lys Lys Met Ala Gly Arg Ala Val Leu Leu Ala Gly Pro	306
60 65 70	
ccc gcc acg ggc aag acg gcg cta gcg ctc ggc ata gcc cag gag ctc Pro Ala Thr Gly Lys Thr Ala Leu Ala Leu Gly Ile Ala Gln Glu Leu	354
75 80 85	
ggc agc aag gtc cct ttc tgt cct atg gta gga tca gaa gtg tac tcc Gly Ser Lys Val Pro Phe Cys Pro Met Val Gly Ser Glu Val Tyr Ser	402
90 95 100	
tgc gag gtc aag aaa act gag gtg ctg atg gaa aat ttc cgt aga gct Ser Glu Val Lys Lys Thr Glu Val Leu Met Glu Asn Phe Arg Arg Ala	450
105 110 115	
ata ggt ttg cgt ata aag gaa aac aaa gag gtt tat gaa gga gag gtt Ile Gly Leu Arg Ile Lys Glu Asn Lys Glu Val Tyr Glu Gly Glu Val	498
120 125 130 135	
act gaa ctt tcc cca gaa gag gct gag agt aca act ggt gga tat gca Thr Glu Leu Ser Pro Glu Glu Ala Glu Ser Thr Thr Gly Gly Tyr Ala	546
140 145 150	
aaa agc att agc cat gta atc atc agc tta aag act gtt aaa ggg act Lys Ser Ile Ser His Val Ile Ile Ser Leu Lys Thr Val Lys Gly Thr	594
155 160 165	
aag caa ctg aag tta gat tct tca att tat gat gct ctg atc aag gaa Lys Gln Leu Lys Leu Asp Ser Ser Ile Tyr Asp Ala Leu Ile Lys Glu	642
170 175 180	
aag gtg gca gtg ggt gat gtt ata tac atc gaa gca aat agt gga gca Lys Val Ala Val Gly Asp Val Ile Tyr Ile Glu Ala Asn Ser Gly Ala	690
185 190 195	
gtg aaa aga gtt ggt aga tgt gat tct ttt gct aca gaa tac gat ctt Val Lys Arg Val Gly Arg Cys Asp Ser Phe Ala Thr Glu Tyr Asp Leu	738
200 205 210 215	
gaa gct gaa gag tat gtt cct atc ccc aaa ggt gaa gtc cat aag aaa Glu Ala Glu Glu Tyr Val Pro Ile Pro Lys Gly Glu Val His Lys Lys	786
220 225 230	
aaa gaa att gtg cag gat gtc aca ctt cat gac ctt gat gca gca aat Lys Glu Ile Val Gln Asp Val Thr Leu His Asp Leu Asp Ala Ala Asn	834
235 240 245	
gct cag cca caa ggt ggc caa gat att ttg tcc ctt atg ggc cag atg Ala Gln Pro Gln Gly Gly Gln Asp Ile Leu Ser Leu Met Gly Gln Met	882
250 255 260	
atg aaa cca cga aag act gaa atc acc gaa aaa cta cgc caa gaa att Met Lys Pro Arg Lys Thr Glu Ile Thr Glu Lys Leu Arg Gln Glu Ile	930
265 270 275	
aat aag gtg gta aat aga tat atc gat gaa gga att gca gag ctt gta Asn Lys Val Val Asn Arg Tyr Ile Asp Glu Gly Ile Ala Glu Leu Val	978
280 285 290 295	

002090.01568560

cct ggt gtt ttg ttc att gat gag gtc cac atg ttg gat atc gaa tgt 1026
 Pro Gly Val Leu Phe Ile Asp Glu Val His Met Leu Asp Ile Glu Cys
 300 305 310
 ttt tct tat ctt aac cgt gca ttg gag agc cca tta tca cca atc gtg 1074
 Phe Ser Tyr Leu Asn Arg Ala Leu Glu Ser Pro Leu Ser Pro Ile Val
 315 320 325
 ata ctt gct aca aat agg gga ata tgt aat gta aga gga act gat atg 1122
 Ile Leu Ala Thr Asn Arg Gly Ile Cys Asn Val Arg Gly Thr Asp Met
 330 335 340
 aca agt cca cat ggt ata cgg gtg gat ctt cta gat agg ctg gtg att 1170
 Thr Ser Pro His Gly Ile Pro Val Asp Leu Leu Asp Arg Leu Val Ile
 345 350 355
 att cgg aca gag aca tat ggc cct act gag atg ata cag ata ttg gct 1218
 Ile Arg Thr Glu Thr Tyr Gly Pro Thr Glu Met Ile Gln Ile Leu Ala
 360 365 370 375
 atc cga gca caa gtg gag gag att gat atg gat gaa gaa agt ctt gct 1266
 Ile Arg Ala Gln Val Glu Glu Ile Asp Met Asp Glu Glu Ser Leu Ala
 380 385 390
 tat tta ggc gag atc gga cag cag aca tct ttg aga cat gct att caa 1314
 Tyr Leu Gly Glu Ile Gly Gln Gln Thr Ser Leu Arg His Ala Ile Gln
 395 400 405
 ttg ata tca cct gcc agc gtg gtc tca aag act aat gga aga gag aaa 1362
 Leu Ile Ser Pro Ala Ser Val Val Ser Lys Thr Asn Gly Arg Glu Lys
 410 415 420
 atc tgc aag gct gat ctc gag gaa gtc agt ggg ctc tat ttg gat gcc 1410
 Ile Cys Lys Ala Asp Leu Glu Glu Val Ser Gly Leu Tyr Leu Asp Ala
 425 430 435
 aaa tcc tcg gct cgg ctg ctc cag gag caa caa gaa aga tac atc acc 1458
 Lys Ser Ser Ala Arg Leu Leu Gln Glu Gln Gln Glu Arg Tyr Ile Thr
 440 445 450 455
 tagatttgga tctcctgtcg ttggaagtctc gaagagaatg tagttgccag ctcgaaagtc 1518
 atctagtcca ttgatctgct tcacaggttc atagtctact ggtcttggag cgagcacatt 1578
 tcgggggggaa cggcttgtaaat ttgcagtgct ctgcttgggt tagctccar agaagacttg 1638
 gttccggcat attgctcggt caagcactgt tcgctgatta gattggtcac cgggtgcagg 1698
 attgcgctgt gtgtttttat cttgctcctc ggtgtccgga gtcgtcctcc acgggttgta 1758
 ttggcccgaa cccatatcttt gtaaccatgg ataattgata ggattcttac agaatgcaac 1818
 ttgcattgct ttattatttc taaatgtcca taaagcataa cgaaatgttt ctacaacmtw 1878
 taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1912

<210> 4

<211> 455

<212> PRT

<213> Zea mays

<400> 4

Met Arg Ile Glu Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala
 1 5 10 15
 Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Ala Asn Gly Met Ala
 20 25 30
 Ile Ala Leu Ala Ala Gly Phe Val Gly Gln Ala Ala Arg Glu Ala
 35 40 45
 Ala Gly Leu Ala Val Asp Met Ile Arg Gln Lys Lys Met Ala Gly Arg

002030.0156550

50 55 60
 Ala Val Leu Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu Ala
 65 70 75 80
 Leu Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met
 85 90 95
 Val Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu
 100 105 110
 Met Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys
 115 120 125
 Glu Val Tyr Glu Gly Glu Val Thr Glu Leu Ser Pro Glu Glu Ala Glu
 130 135 140
 Ser Thr Thr Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Ser
 145 150 155 160
 Leu Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Ser Ser Ile
 165 170 175
 Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr
 180 185 190
 Ile Glu Ala Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser
 195 200 205
 Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile Pro
 210 215 220
 Lys Gly Glu Val His Lys Lys Lys Glu Ile Val Gln Asp Val Thr Leu
 225 230 235 240
 His Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile
 245 250 255
 Leu Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr
 260 265 270
 Glu Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp
 275 280 285
 Glu Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val
 290 295 300
 His Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu
 305 310 315 320
 Ser Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys
 325 330 335
 Asn Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp
 340 345 350
 Leu Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr
 355 360 365
 Glu Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile Asp
 370 375 380
 Met Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr
 385 390 395 400
 Ser Leu Arg His Ala Ile Gln Leu Ile Ser Pro Ala Ser Val Val Ser
 405 410 415
 Lys Thr Asn Gly Arg Glu Lys Ile Cys Lys Ala Asp Leu Glu Glu Val
 420 425 430
 Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Gln Glu
 435 440 445
 Gln Gln Glu Arg Tyr Ile Thr
 450 455

<210> 5
 <211> 1886
 <212> DNA
 <213> Zea mays

<220>
 <221> CDS
 <222> (82) ... (1446)

<400> 5

00589510-060700

tcgacccacg cgtccggcgg cggccggcgg gagagagcag ctctagagag aacagagagc 60
gcataactag cggcggcggc g atg agg ata gag gag gtg caa tcg acc tcg 111
Met Arg Ile Glu Glu Val Gln Ser Thr Ser
1 5 10

aag aag cag cgc atc gcc acc cac act cac atc aag ggc ctc ggc ctc 159
Lys Lys Gln Arg Ile Ala Thr His Thr His Ile Lys Gly Leu Gly Leu
15 20 25

gac gcc aat gga atg tcg atg ccg ttg gcg gcg ggg ttc gtg ggc cag 207
Asp Ala Asn Gly Met Ser Met Pro Leu Ala Ala Gly Phe Val Gly Gln
30 35 40

gcg gcg gcg cgc gag gcg gcc ggg ctg gcg gtc gac atg atc cgc cag 255
Ala Ala Ala Arg Glu Ala Ala Gly Leu Ala Val Asp Met Ile Arg Gln
45 50 55

aag aag atg gcc ggt cgc gcg ctg ctc ctt gcg ggc ccg ccc gcc acg 303
Lys Lys Met Ala Gly Arg Ala Leu Leu Leu Ala Gly Pro Pro Ala Thr
60 65 70

ggc aaa acg gcg cta gcg ctc ggc ata gcg cag gag ctc ggc agc aag 351
Gly Lys Thr Ala Leu Ala Leu Gly Ile Ala Gln Glu Leu Gly Ser Lys
75 80 85 90

gtc cca ttc tgt cct atg gta gga tca gaa gtg tac tcc tca gag gtc 399
Val Pro Phe Cys Pro Met Val Gly Ser Glu Val Tyr Ser Ser Glu Val
95 100 105

aag aaa act gag gtg ctg atg gaa aat ttc cgt aga gct ata ggt ttg 447
Lys Lys Thr Glu Val Leu Met Glu Asn Phe Arg Arg Ala Ile Gly Leu
110 115 120

cgt ata aag gaa aac aaa gag gtt tat gaa gga gag gtt att gaa ctt 495
Arg Ile Lys Glu Asn Lys Glu Val Tyr Glu Gly Glu Val Ile Glu Leu
125 130 135

tcc cca gaa gag gct gag agc aca act ggt gga tat gcg aaa agc att 543
Ser Pro Glu Glu Ala Glu Ser Thr Thr Gly Gly Tyr Ala Lys Ser Ile
140 145 150

agc cac gta atc att ggc tta aag act gtc aaa ggg act aag caa ttg 591
Ser His Val Ile Ile Gly Leu Lys Thr Val Lys Gly Thr Lys Gln Leu
155 160 165 170

aaa tta gac cct tca att tat gat gct ttg atc aag gaa aag gtg gca 639
Lys Leu Asp Pro Ser Ile Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala
175 180 185

gtg ggt gat gtt ata tac att gaa gca aat agt gga gca gtg aaa aga 687
Val Gly Asp Val Ile Tyr Ile Glu Ala Asn Ser Gly Ala Val Lys Arg
190 195 200

gtt ggt aga tgt gat tct ttt gct aca gaa tat gat ctt gaa gct gaa 735
Val Gly Arg Cys Asp Ser Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu
205 210 215

gag tat gtt cct atc ccc aaa ggt gaa gtc cat aag aaa aag gaa ata 783
Glu Tyr Val Pro Ile Pro Lys Gly Glu Val His Lys Lys Lys Glu Ile
220 225 230

002090.0156560

gtg cag gat gtc aca ctc cat gac ctt gat gca gca aat gcc cag cca	831
Val Gln Asp Val Thr Leu His Asp Leu Asp Ala Ala Asn Ala Gln Pro	
235 240 245 250	
caa ggt ggc caa gat att ttg tcc ctt atg ggc cag atg atg aag cca	879
Gln Gly Gly Gln Asp Ile Leu Ser Leu Met Gly Gln Met Met Lys Pro	
255 260 265	
cgg aag act gaa atc acc gaa aag cta cgc caa gaa atc aat aag gtg	927
Arg Lys Thr Gln Ile Thr Glu Lys Leu Arg Gln Glu Ile Asn Lys Val	
270 275 280	
gta aac aga tat atc gac gaa gga atc gca gag ctt gta cct ggt gtt	975
Val Asn Arg Tyr Ile Asp Glu Gly Ile Ala Glu Leu Val Pro Gly Val	
285 290 295	
ttg ttc att gat gag gtc cac atg ttg gat att gaa tgc ttt tct tat	1023
Leu Phe Ile Asp Glu Val His Met Leu Asp Ile Glu Cys Phe Ser Tyr	
300 305 310	
ctt aac cgt gca ttg gag agc cca tta tca cca att gtg ata ctc gct	1071
Leu Asn Arg Ala Leu Glu Ser Pro Leu Ser Pro Ile Val Ile Leu Ala	
315 320 325 330	
acg aat aga gga ata tgt aat gtg aga gga acc gat atg acg agt cca	1119
Thr Asn Arg Gly Ile Cys Asn Val Arg Gly Thr Asp Met Thr Ser Pro	
335 340 345	
cat ggt ata cca gtg gac ctt cta gat agg ttg gtg att att cgg aca	1167
His Gly Ile Pro Val Asp Leu Leu Asp Arg Leu Val Ile Ile Arg Thr	
350 355 360	
gaa aca tat ggc cct act gag atg ata cag ata ctg gct atc cga gca	1215
Glu Thr Tyr Gly Pro Thr Glu Met Ile Gln Ile Leu Ala Ile Arg Ala	
365 370 375	
caa gtg gaa gag att gat atc gat gaa gaa agt ctt gct tat tta ggc	1263
Gln Val Glu Glu Ile Asp Ile Asp Glu Glu Ser Leu Ala Tyr Leu Gly	
380 385 390	
gag atc gga cag cag aca tct ttg aga cat gct att cag ttg cta tca	1311
Glu Ile Gly Gln Gln Thr Ser Leu Arg His Ala Ile Gln Leu Leu Ser	
395 400 405 410	
cct gcc agc gtg gtc gca aag acc aac ggg aga gaa aag atg tgc aag	1359
Pro Ala Ser Val Val Ala Lys Thr Asn Gly Arg Glu Lys Met Cys Lys	
415 420 425	
gct gac ctc gag gaa gtc agc ggg ctc tat ttg gat gcc aaa tcc tcg	1407
Ala Asp Leu Glu Glu Val Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser	
430 435 440	
gct cgc ctg ctc cag gag caa caa gaa aga tac atc acc tagacttgca	1456
Ala Arg Leu Leu Gln Glu Gln Gln Glu Arg Tyr Ile Thr	
445 450 455	
tctcctgctg ttggaaggaaa agcctcgaag agaaaatgcat tctgcaaagt cgcgtcatct	1516
gcttcagtat gtgtagtct acaagtcttg gagagagcact gttcttcggt ggaaggaaaa	1576
ctgttgaaat ttgttagtac ctgttttttt tttagcctoca gogaagactt gattccggca	1636
tggtgtgtgt tcaacgacgg ttaacaccga ttaagatttg cccagccgtg caggaaattgc	1696
cgggtgtgtt ttcaccocct cgctaatacga tgtccagaat ctgtgtgccc acgggtgtgtg	1756
tattgacctt agctttgttaa ccattgcacat gatttctttt ttaacgctga tggatggcac	1816

00589510-060700

ctggatctct gtccatggcc atcgtaatcc cactgtctgg agcagggttt catgaaaaaa 1876
 aaaaaaaaaa 1886

<210> 6
 <211> 455
 <212> PRT
 <213> Zea mays

<400> 6
 Met Arg Ile Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala
 1 5 10 15
 Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Ala Asn Gly Met Ser
 20 25 30
 Met Pro Leu Ala Ala Gly Phe Val Gly Gln Ala Ala Arg Glu Ala
 35 40 45
 Ala Gly Leu Ala Val Asp Met Ile Arg Gln Lys Lys Met Ala Gly Arg
 50 55 60
 Ala Leu Leu Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu Ala
 65 70 75 80
 Leu Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met
 85 90 95
 Val Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu
 100 105 110
 Met Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys
 115 120 125
 Glu Val Tyr Glu Gly Glu Val Ile Glu Leu Ser Pro Glu Glu Ala Glu
 130 135 140
 Ser Thr Thr Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Gly
 145 150 155 160
 Leu Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Pro Ser Ile
 165 170 175
 Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr
 180 185 190
 Ile Glu Ala Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser
 195 200 205
 Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile Pro
 210 215 220
 Lys Gly Glu Val His Lys Lys Glu Ile Val Gln Asp Val Thr Leu
 225 230 235 240
 His Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile
 245 250 255
 Leu Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr
 260 265 270
 Glu Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp
 275 280 285
 Glu Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val
 290 295 300
 His Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu
 305 310 315 320
 Ser Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys
 325 330 335
 Asn Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp
 340 345 350
 Leu Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr
 355 360 365
 Glu Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile Asp
 370 375 380
 Ile Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr
 385 390 395 400
 Ser Leu Arg His Ala Ile Gln Leu Leu Ser Pro Ala Ser Val Val Ala
 405 410 415
 Lys Thr Asn Gly Arg Glu Lys Met Cys Lys Ala Asp Leu Glu Val

09589510.060700

420 425 430
 Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Gln Glu
 435 440 445
 Gln Gln Glu Arg Tyr Ile Thr
 450 455

 <210> 7
 <211> 1898
 <212> DNA
 <213> Zea mays

 <220>
 <221> CDS
 <222> (166)...(1533)

 <400> 7
 attacgccaa gctctaatac gactcactat agggaaagct ggtacgcctg cagggtaccgg 60
 tccggaattc ccgggtcgac ccacgcgtcc gtgccttgag gcgcgcggcg gcgggagaga 120
 gcagctctag agagaacaga gagcgcataa ctacgcgcgg cggcgc atg agg ata gag 177
 Met Arg Ile Glu
 1

 gag gtg caa tog acc tog aag aag cag cgc atc gcc acc cac act cac 225
 Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala Thr His Thr His
 5 10 15 20

 atc aag ggc ctc ggc ctc gac cag gcc aat gga atg tcg atg ccg ttg 273
 Ile Lys Gly Leu Gly Leu Asp Gln Ala Asn Gly Met Ser Met Pro Leu
 25 30 35

 gcg gcg ggg ttc gtg ggc cag gcg gcg gcg cgc gag gcg gcc ggg ctg 321
 Ala Ala Gly Phe Val Gly Gln Ala Ala Arg Glu Ala Ala Gly Leu
 40 45 50

 gcg gtc gac atg atc cgc cag aag aag atg gcc ggt cgc gcg ctg ctc 369
 Ala Val Asp Met Ile Arg Gln Lys Lys Met Ala Gly Arg Ala Leu Leu
 55 60 65

 ctt gcg ggc ccg ccc gcc acg ggc aaa acg gcg cta gcg ctc ggc ata 417
 Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu Ala Leu Gly Ile
 70 75 80

 gcg cag gag ctc ggc agc aag gtc cca ttc tgt cct atg gta gga tca 465
 Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met Val Gly Ser
 85 90 95 100

 gaa gtg tac tcc tca gag gtc aag aaa act gag gtg ctg atg gaa aat 513
 Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu Met Glu Asn
 105 110 115

 ttc cgt aga gct ata ggt ttg cgt ata aag gaa aac aaa gag gtt tat 561
 Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys Glu Val Tyr
 120 125 130

 gaa gga gag gtt att gaa ctt tcc cca gaa gag gct gag agc aca act 609
 Glu Gly Glu Val Ile Glu Leu Ser Pro Glu Glu Ala Glu Ser Thr Thr
 135 140 145

 ggt gga tat gcg aaa agc att agc cac gta atc att ggc tta aag act 657
 Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Gly Leu Lys Thr
 150 155 160

002090.0585560

gtc aaa ggg act aag caa ttg aaa tta gac cct tca att tat gat gct Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Pro Ser Ile Tyr Asp Ala 165 170 175 180	705
ttg atc aag gaa aag gtg gca gtg ggt gat gtt ata tac att gaa gca Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr Ile Glu Ala 185 190 195	753
aat agt gga gca gtg aaa aga gtt ggt aga tgt gat tct ttt gct aca Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser Phe Ala Thr 200 205 210	801
gaa tat gat ctt gaa gct gaa gag tat gtt cct atc ccc aaa ggt gaa Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile Pro Lys Gly Glu 215 220 225	849
gtc cat aag aaa aag gaa ata gtg cag gat gtc aca ctc cat gac ctt Val His Lys Lys Lys Glu Ile Val Gln Asp Val Thr Leu His Asp Leu 230 235 240	897
gat gca gca aat gcc cag caa ggt ggc caa gat att ttg tcc ctt Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile Leu Ser Leu 245 250 255 260	945
atg ggc cag atg atg aag cca cgg aag act gaa atc acc gaa aag cta Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr Glu Lys Leu 265 270 275	993
cgc caa gaa atc aat aag gtg gta aac aga tat atc gac gaa gga atc Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp Glu Gly Ile 280 285 290	1041
gca gag ctt gta cct ggt gtt ttg ttc att gat gag gtc cac atg ttg Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val His Met Leu 295 300 305	1089
gat att gaa tgc ttt tct tat ctt aac cgt gca ttg gag agc cca tta Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu Ser Pro Leu 310 315 320	1137
tca cca att gtg ata ctc gct acg aat aga gga ata tgt aat gtg aga Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys Asn Val Arg 325 330 335 340	1185
gga acc gat atg acg agt cca cat ggt ata cca gtg gac ctt cta gat Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp Leu Leu Asp 345 350 355	1233
agg ttg gtg att att cgg aca gaa aca tat ggc cct act gag atg ata Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr Glu Met Ile 360 365 370	1281
cag ata ctg gct atc cga gca caa gtg gaa gag att gat atc gat gaa Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile Asp Ile Asp Glu 375 380 385	1329
gaa agt ctt gct tat tta ggc gag atc gga cag cag aca tct ttg aga Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr Ser Leu Arg 390 395 400	1377
cat gct att cag ttg cta cct gcc agc gtg gtc gca aag acc aac His Ala Ile Gln Leu Leu Ser Pro Ala Ser Val Val Ala Lys Thr Asn	1425

0058510-060700

405 410 415 420

ggg aga gaa aag atg tgc aag gct gac ctc gag gaa gtc agc ggg ctc 1473
 Gly Arg Glu Lys Met Cys Lys Ala Asp Leu Glu Glu Val Ser Gly Leu
 425 430 435

tat ttg gat gcc aaa tcc tgc gct cgc ctg ctc cag gag caa caa gaa 1521
 Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Glu Gln Gln Glu
 440 445 450

aga tac atc acc tagacttgca tctcctgctg tggaaggaaa agcctcgaag 1573
 Arg Tyr Ile Thr
 455

agaaatgcat tctgcaaagt gcgtcgatct gcttcagtat gtcgtagtct acaagctcttg 1633
 gagagagcac gtttctgcgg ggaaggaaaa ctgtttgaaat tttgtagtac ctgtttttttg 1693
 ttagcctcca gcgaagactt gattccggca tattgcttgt tcacgcaccg ttaacaccga 1753
 ttaagattgg ccacagcctg caggaattgc cgggtgtgtt ttcacccctc cgctaatacga 1813
 tgtccagaaat ctgtgtgccc acgggtgttg tattgacctt agctttgttaa ccatgcacat 1873
 gattttcttta aaaaaaaaaa aaaaa 1898

<210> 8
 <211> 456
 <212> PRT
 <213> Zea mays

<400> 8

Met Arg Ile Glu Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala
 1 5 10 15
 Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Gln Ala Asn Gly Met
 20 25 30
 Ser Met Pro Leu Ala Ala Gly Phe Val Gly Gln Ala Ala Arg Glu
 35 40 45
 Ala Ala Gly Leu Ala Val Asp Met Ile Arg Gln Lys Lys Met Ala Gly
 50 55 60
 Arg Ala Leu Leu Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu
 65 70 75 80
 Ala Leu Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro
 85 90 95
 Met Val Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val
 100 105 110
 Leu Met Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn
 115 120 125
 Lys Glu Val Tyr Glu Gly Glu Val Ile Glu Leu Ser Pro Glu Glu Ala
 130 135 140
 Glu Ser Thr Thr Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile
 145 150 155 160
 Gly Leu Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Pro Ser
 165 170 175
 Ile Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile
 180 185 190
 Tyr Ile Glu Ala Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp
 195 200 205
 Ser Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile
 210 215 220
 Pro Lys Gly Glu Val His Lys Lys Lys Glu Ile Val Gln Asp Val Thr
 225 230 235 240
 Leu His Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp
 245 250 255
 Ile Leu Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile
 260 265 270
 Thr Glu Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile

00589510.01560700

```

      275              280              285
Asp Glu Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu
290              295              300
Val His Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu
305              310              315
Glu Ser Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile
      325              330              335
Cys Asn Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val
      340              345              350
Asp Leu Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro
      355              360              365
Thr Glu Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile
      370              375              380
Asp Ile Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln
      385              390              395
Thr Ser Leu Arg His Ala Ile Gln Leu Leu Ser Pro Ala Ser Val Val
      405              410              415
Ala Lys Thr Asn Gly Arg Glu Lys Met Cys Lys Ala Asp Leu Glu Glu
      420              425              430
Val Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Gln
      435              440              445
Glu Gln Gln Glu Arg Tyr Ile Thr
      450              455

```

<210> 9

<211> 1869

<212> DNA

<213> Zea mays

<220>

<221> CDS

<222> (64)...(1377)

<400> 9

```

cgaccacgcg gtcggggcag ctccacagaa acagagagcg cataaccggc ggcgttggcg      60
gcg atg agg atc gag gag gtg cag tcg acc tcg aag aag cag cgc atc      108
  Met Arg Ile Glu Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile
    1              5              10              15

gcc acc cac acc cac atc aag gga ctc gcc ctc gac gcc aat ggg atg      156
Ala Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Ala Asn Gly Met
              20              25              30

gcg att gcg ttg gcg gcg ggg ttc gtg gcc cag aag aag atg gcc ggc      204
Ala Ile Ala Leu Ala Ala Gly Phe Val Gly Gln Lys Lys Met Ala Gly
              35              40              45

cgc gcg gtg ctc ctt gcg ggt ccg ccc gcc acg gcc aag acg gcg cta      252
Arg Ala Val Leu Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu
              50              55              60

gcg gcc ata gcc cag gag ctc gcc agc aag gtc cct ttc tgt cct atg      300
Ala Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met
              65              70              75

gta gga tca gaa gtg tac tcc tcg gag gtc aag aaa act gag gtg ctg      348
Val Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu
              80              85              90              95

atg gaa aat ttc cgt aga gct ata ggt ttg cgt ata aag gaa aac aaa      396
Met Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys
              100              105              110

```

09589510-060700

gag gtt tat gaa gga gag gtt act gaa ctt tcc cca gaa gag gct gag Glu Val Tyr 115 Glu Gly Glu Val Thr 120 Leu Ser Pro Glu Glu Ala Glu 125	444
agt aca act ggt gga tat gca aaa agc att agc cat gta atc atc agc Ser Thr 130 Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Ser 135 140	492
tta aag act gtt aaa ggg act aag caa ctg aag tta gat tct tca att Leu Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Ser Ser Ile 145 150 155	540
tat gat gct ctg atc aag gaa aag gtg gca gtg ggt gat gtt ata tac Tyr Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr 160 165 170 175	588
atc gaa gca aat agt gga gca gtg aaa aga gtt ggt aga tgt gat tct Ile Glu Ala Asn 180 Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser 185 190	636
ttt gct aca gaa tac gat ctt gaa gct gaa gag tat gtt cct atc ccc Phe Ala Thr Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile Pro 195 200 205	684
aaa ggt gaa gtc cat aag aaa aaa gaa att gtg cag gat gtc aca ctt Lys Gly Glu Val His Lys Lys Lys Glu Ile Val Gln Asp Val Thr Leu 210 215 220	732
cat gac ctt gat gca gca aat gct cag cca caa ggt ggc caa gat att His Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile 225 230 235	780
ttg tcc ctt atg ggc cag atg atg aaa cca cga aag act gaa atc acc Leu Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr 240 245 250 255	828
gaa aaa cta cgc caa gaa att aat aag gtg gta aat aga tat atc gat Glu Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp 260 265 270	876
gaa gga att gca gag ctt gta cct ggt gtt ttg ttc att gat gag gtc Glu Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val 275 280 285	924
cac atg ttg gat atc gaa tgt ttt tct tat ctt aac cgt gca ttg gag His Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu 290 295 300	972
agc cca tta tca cca atc gtg ata ctt gct aca aat agg gga ata tgt Ser Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys 305 310 315	1020
aat gta aga gga act gat atg aca agt cca cat ggt ata cgg gtg gat Asn Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp 320 325 330 335	1068
ctt cta gat agg ctg gtg att att cgg aca gag aca tat ggc cct act Leu Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr 340 345 350	1116

09569510.060700

gag atg ata cag ata ttg gct atc cga gca caa gtg gag gag att gat 1164
 Glu Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile Asp 365
 355 360 365

atg gat gaa gaa agt ctt gct tat tta ggc gag atc gga cag cag aca 1212
 Met Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr 370 375 380

tct ttg aga cat gct att caa ttg ata tca cct gcc agc gtg gtc tca 1260
 Ser Leu Arg His Ala Ile Gln Leu Ile Ser Pro Ala Ser Val Val Ser 385 390 395

aag act aat gga aga gag aaa atc tgc aag gct gat ctc gag gaa gtt 1308
 Lys Thr Asn Gly Arg Glu Lys Ile Cys Lys Ala Asp Leu Glu Glu Val 400 405 410 415

agt ggg ctc tat ttg gat gcc aaa tcc tgc gct cgg ctg ctc cag gag 1356
 Ser Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Gln Glu 420 425 430

caa caa gaa aga tac atc acc tagatttggg tcacctgtcg tggaagtctc 1407
 Gln Gln Glu Arg Tyr Ile Thr 435

gaagagaatg tagttgccag ctogaaagtc atctagttaa ttgatctgct tcacaggtct 1467
 tggagcgagc acatttcggg gggaacggct tgaattttgc agtgccctgct tgtgttagtc 1527
 tccagagaag acttggtacc ggcattattgc ctgttcaacg actgttctgct gattagattg 1587
 gtcaacgggtg caggaattgc cgtgtgtgtt ttttatcttg ctcatcggtg tccggaatct 1647
 gtgcctccac gggttgtatt ggcocgaacc ctatctttgt aaccatggat aatggatagc 1707
 attcttcacg aatgcaactt gcatggcttt attattcta aatgtccata aagcttaaca 1767
 aaatgtttct acaacatata gacctcctgc ccaaatataa attggtttta gcttagataa 1827
 ttaatgggta catacactac tttatgtaaa aaaaaaaaaa aa 1869

<210> 10
 <211> 438
 <212> PRT
 <213> Zea mays

<400> 10
 Met Arg Ile Glu Glu Val Gln Ser Thr Ser Lys Lys Gln Arg Ile Ala
 1 5 10 15
 Thr His Thr His Ile Lys Gly Leu Gly Leu Asp Ala Asn Gly Met Ala
 20 25 30
 Ile Ala Leu Ala Ala Gly Phe Val Gly Gln Lys Lys Met Ala Gly Arg
 35 40 45
 Ala Val Leu Leu Ala Gly Pro Pro Ala Thr Gly Lys Thr Ala Leu Ala
 50 55 60
 Gly Ile Ala Gln Glu Leu Gly Ser Lys Val Pro Phe Cys Pro Met Val
 65 70 75 80
 Gly Ser Glu Val Tyr Ser Ser Glu Val Lys Lys Thr Glu Val Leu Met
 85 90 95
 Glu Asn Phe Arg Arg Ala Ile Gly Leu Arg Ile Lys Glu Asn Lys Glu
 100 105 110
 Val Tyr Glu Gly Glu Val Thr Glu Leu Ser Pro Glu Glu Ala Glu Ser
 115 120 125
 Thr Thr Gly Gly Tyr Ala Lys Ser Ile Ser His Val Ile Ile Ser Leu
 130 135 140
 Lys Thr Val Lys Gly Thr Lys Gln Leu Lys Leu Asp Ser Ser Ile Tyr
 145 150 155 160
 Asp Ala Leu Ile Lys Glu Lys Val Ala Val Gly Asp Val Ile Tyr Ile
 165 170 175
 Glu Ala Asn Ser Gly Ala Val Lys Arg Val Gly Arg Cys Asp Ser Phe

09589510.060700

```

180      185      190
Ala Thr Glu Tyr Asp Leu Glu Ala Glu Glu Tyr Val Pro Ile Pro Lys
195      200      205
Gly Glu Val His Lys Lys Lys Glu Ile Val Gln Asp Val Thr Leu His
210      215      220
Asp Leu Asp Ala Ala Asn Ala Gln Pro Gln Gly Gly Gln Asp Ile Leu
225      230      235
Ser Leu Met Gly Gln Met Met Lys Pro Arg Lys Thr Glu Ile Thr Glu
245      250      255
Lys Leu Arg Gln Glu Ile Asn Lys Val Val Asn Arg Tyr Ile Asp Glu
260      265      270
Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe Ile Asp Glu Val His
275      280      285
Met Leu Asp Ile Glu Cys Phe Ser Tyr Leu Asn Arg Ala Leu Glu Ser
290      295      300
Pro Leu Ser Pro Ile Val Ile Leu Ala Thr Asn Arg Gly Ile Cys Asn
305      310      315
Val Arg Gly Thr Asp Met Thr Ser Pro His Gly Ile Pro Val Asp Leu
325      330      335
Leu Asp Arg Leu Val Ile Ile Arg Thr Glu Thr Tyr Gly Pro Thr Glu
340      345      350
Met Ile Gln Ile Leu Ala Ile Arg Ala Gln Val Glu Glu Ile Asp Met
355      360      365
Asp Glu Glu Ser Leu Ala Tyr Leu Gly Glu Ile Gly Gln Gln Thr Ser
370      375      380
Leu Arg His Ala Ile Gln Leu Ile Ser Pro Ala Ser Val Val Ser Lys
385      390      395
Thr Asn Gly Arg Glu Lys Ile Cys Lys Ala Asp Leu Glu Glu Val Ser
405      410      415
Gly Leu Tyr Leu Asp Ala Lys Ser Ser Ala Arg Leu Leu Gln Glu Gln
420      425      430
Gln Glu Arg Tyr Ile Thr
435

```

```

<210> 11
<211> 36
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Designed oligonucleotide based upon an adaptor
      used for cDNA library construction and poly(dT) to
      remove clones which have a poly(A) tail but no
      cDNA insert.

```

```

<400> 11
tcgacccacg cgtccgaaaa aaaaaaaaaa aaaaaa

```